

# Interferons: cell signalling, immune modulation, antiviral responses and virus countermeasures

S. Goodbourn,<sup>1</sup> L. Didcock<sup>2</sup> and R. E. Randall<sup>2</sup>

<sup>1</sup> Department of Biochemistry and Immunology, St George's Hospital Medical School, University of London, London SW17 0RE, UK

<sup>2</sup> Biomolecular Sciences Building, North Haugh, University of St Andrews, Fife KY16 9TS, UK

## Introduction

To establish infections *in vivo*, viruses must replicate in the face of powerful immune defence mechanisms including those induced by interferons (IFNs). The effectiveness of the IFN response has led to many viruses developing specific mechanisms that antagonize the production or actions of IFNs. Indeed, in order to replicate efficiently *in vivo*, it seems likely that all viruses must, at least to a degree, have some means of circumventing the IFN response either by limiting IFN production or by blocking IFN actions. However, virus countermeasures to the IFN response are rarely absolute and the IFN response, by limiting virus spread, buys time for the generation of an acquired immune response to the invading virus. Nevertheless, the speed and efficiency by which a given virus circumvents the IFN response may be critical determinants in its host range and pathogenicity. In part A of this article, we review how virus infections lead to the production of IFNs (section 1), how IFNs induce the transcription of their target genes (section 2) and how these target genes exert their antiviral effects (section 3). Part B of this article reviews the strategies used by viruses to inhibit IFN production (section 4), IFN signalling (section 5) and/or specific antiviral functions (section 6).

The IFNs are a large family of multifunctional secreted proteins involved in antiviral defence, cell growth regulation and immune activation. The IFNs may be classified into two distinct types. Type I IFNs are produced in direct response to virus infection and consist of the products of the IFN- $\alpha$  multigene family, which are predominantly synthesized by leukocytes, and the product of the IFN- $\beta$  gene, which is synthesized by most cell types but particularly by fibroblasts. Type II IFN consists of the product of the IFN- $\gamma$  gene and, rather than being induced directly by virus infection, is synthesized in response to the recognition of infected cells by activated T lymphocytes and natural killer (NK) cells (reviewed in Vilcek & Sen, 1996).


Type I IFN (IFN- $\alpha/\beta$ ) and type II IFN (IFN- $\gamma$ ) share no obvious structural homology. However, functional similarities exist due to a broad overlap in the types of genes that they induce (reviewed in Stark *et al.*, 1998; summarized in Fig. 1). It is clear that IFNs can induce transcription of a significant number of genes. In addition to the well-characterized gene products described below, large-scale screening using oligonucleotide arrays has identified several novel human IFN-inducible genes that are induced by either IFN- $\alpha/\beta$  or IFN- $\gamma$  or both (Der *et al.*, 1998). The importance of IFN in mediating responses to virus infections is established by the fact that mice lacking IFN- $\alpha/\beta$  (Muller *et al.*, 1994; Fiette *et al.*, 1995; Hwang *et al.*, 1995; Rousseau *et al.*, 1995; Steinhoff *et al.*, 1995; van den Broek *et al.*, 1995a, b; Garcia-Sastre *et al.*, 1998; Mrkic *et al.*, 1998; Yeow *et al.*, 1998; Cousens *et al.*, 1999; Grieder & Vogel, 1999; Grob *et al.*, 1999; Johnson & Roehrig, 1999; Nunez, 1999) or IFN- $\gamma$  (Huang *et al.*, 1993; Muller *et al.*, 1994; Fiette *et al.*, 1995; van den Broek *et al.*, 1995a, b; Bovolenta *et al.*, 1999; Cantin *et al.*, 1999; Dorman *et al.*, 1999; Grob *et al.*, 1999; Nunez, 1999; Tay *et al.*, 1999) receptors are unable to mount efficient responses to a large number of viruses. Importantly, there are often differences in the requirements for the two types of IFN in resolving specific virus infections, and the systems are non-redundant in many cases. Both types of IFN stimulate an 'antiviral state' in target cells, whereby the replication of virus is blocked or impaired due to the synthesis of a number of enzymes that interfere with cellular and virus processes. Both types of IFN can also slow the growth of target cells or make them more susceptible to apoptosis, thereby limiting the extent of virus spread. Finally, both types of IFN have profound immunomodulatory effects and stimulate the adaptive response. However, whilst both IFN- $\alpha/\beta$  and IFN- $\gamma$  influence the properties of immune effector cells, they show significant differences, and it is these extended cytokine functions that probably account for the different spectrums of antiviral activities of the two types of IFN.

## A. Production and actions of IFNs

### 1. Virus induction of IFN genes

The induction of IFN- $\beta$  expression by virus infection of fibroblastoid cells has been the subject of intensive research. It

**Authors for correspondence:** Steve Goodbourn (fax +44 20 8725 2992; e-mail s.goodbourn@sghms.ac.uk) and Rick Randall (fax +44 1334 462595; e-mail rer@st-andrews.ac.uk)



**Fig. 1.** The biological properties of  $\alpha/\beta$  and  $\gamma$  IFNs. IFNs  $\alpha/\beta$  and  $\gamma$  bind to specific surface receptors on primary target cells and induce the transcription of a variety of genes that mount an antiviral response. It is characteristic of these gene products that they often depend upon viral dsRNA as a co-factor in order to ensure that they are only active under conditions of infection. Thus, PKR and 2'-5' oligoadenylate synthetase (OAS) are synthesized as inactive precursors (PKRi and OASi, respectively) and are activated by dsRNA (PKRa and OASa, respectively). Once activated, these gene products shut down translation. IFNs can also induce the synthesis of gene products that arrest the cell cycle (e.g. p21, an inhibitor of G<sub>1</sub>/S phase-specific cyclin-dependent kinases), thus blocking virus replication, or induce a pro-apoptotic state (e.g. procaspases). Finally, IFNs can induce the synthesis of proteins that are involved in the processing and presentation of virus proteins to CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) (e.g. MHC class I proteins, components of the proteasome and peptide transporter molecules). Both types of IFN also have profound immunomodulatory effects that differ between types, and these are discussed in the text.

is generally assumed that the inducer is intracellular double-stranded RNA (dsRNA), provided by the viral genome itself or formed as a result of replication or convergent transcription of viral genomes (reviewed in Jacobs & Langland, 1996). The induction of IFN- $\beta$  occurs primarily at the level of transcriptional initiation (see Fig. 2). The key induction event is the redistribution from the cytoplasm to the nucleus of the transcription factor NF- $\kappa$ B (Lenardo *et al.*, 1989; Visvanathan & Goodbourn, 1989). NF- $\kappa$ B plays a role in the transcriptional induction of many immunomodulatory genes, including other cytokines, MHC class I and cell adhesion molecules (reviewed in Baldwin, 1996). NF- $\kappa$ B is normally held in a quiescent state in the cytoplasm by association with an inhibitor molecule called I $\kappa$ B. Upon receipt of a wide range of stress signals [for example lipopolysaccharide, tumour necrosis factor (TNF), interleukin (IL)-1 and viral dsRNA], I $\kappa$ B becomes phosphorylated by a specific multicomponent I $\kappa$ B kinase and, in turn, the phosphorylated I $\kappa$ B becomes ubiquitinated by an E3 ubiquitin ligase. The ubiquitinated I $\kappa$ B is itself a target for degradation by proteasomes and, once the inhibitory I $\kappa$ B is destroyed, the associated NF- $\kappa$ B is freed from restraint and can enter the nucleus and activate transcription (reviewed in Israel, 2000). Exposure to dsRNA activates NF- $\kappa$ B via the dsRNA-dependent protein kinase R (PKR) (Maran *et al.*, 1994; Yang *et al.*, 1995; see section 3), which activates the IKK $\beta$  subunit of the multicomponent I $\kappa$ B kinase (Chu *et al.*, 1999; Zamanian-Daryoush *et al.*, 2000). PKR can also phosphorylate I $\kappa$ B directly

(Kumar *et al.*, 1994; Offermann *et al.*, 1995), although the biological role for this is unclear.

NF- $\kappa$ B binds to the IFN- $\beta$  promoter as part of a multiprotein transcription-promoting complex called the 'enhanceosome' (reviewed in Thanos, 1996), which also contains HMG-I/Y, ATF-2 homodimers or ATF-2/c-Jun heterodimers (Du *et al.*, 1993) and a factor that binds to positive regulatory domain I (PRD I). Although the latter would appear to be a member of the interferon regulatory factor (IRF) family, its identity remains the subject of debate, having been suggested to be IRF-1 (Miyamoto *et al.*, 1988; Fujita *et al.*, 1989a; Watanabe *et al.*, 1991; Reis *et al.*, 1992; Matsuyama *et al.*, 1993), ISGF3 (Yoneyama *et al.*, 1996), IRF-3 (Sato *et al.*, 1998b; Schafer *et al.*, 1998; Weaver *et al.*, 1998; Yoneyama *et al.*, 1998) or a combination of IRF-3 and IRF-7 (Wathelet *et al.*, 1998). Since many of the IRF proteins bind both PRD I and the closely related IFN-stimulated response element (ISRE; an element that is found in genes that are transcriptionally responsive to type I IFN – see section 2), there may be some functional overlap in the properties of these proteins. One consequence of this overlap may be to ensure that virus infections cannot block IFN- $\beta$  induction completely by inhibiting any single IRF (see section 4).

IFN- $\alpha$  can also be induced by virus infection in fibroblastoid cells, and the promoters of several IFN- $\alpha$  genes have been studied in detail (reviewed in Pitha & Au, 1995). Unlike IFN- $\beta$ , the IFN- $\alpha$  promoters do not have an NF- $\kappa$ B site, but contain




Fig. 2. Transcriptional induction of the IFN- $\beta$  gene. Virus replication gives rise to dsRNA, which is able to activate PKR and perhaps additional cellular kinases. PKR in turn activates the I $\kappa$ B kinase and indirectly leads to the activation of the immunomodulatory transcription factor NF- $\kappa$ B. Together with ATF-2 and a member(s) of the IRF family, NF- $\kappa$ B assembles on the IFN- $\beta$  promoter with the help of several copies of the accessory factor HMG1/Y to form a multifactorial complex called the 'enhanceosome'. Components of the enhanceosome make contacts with factors that are part of the basal transcriptional machinery and, by stabilizing interactions with this machinery and causing a local 'remodelling' of the chromatin, recruit RNA polymerase II to the promoter to bring about transcription of the IFN- $\beta$  gene. See text for details.

elements that are related to the PRD I- and ATF-2-binding sites, as well as distinct elements. IFN- $\alpha$  genes are not able to be induced in embryonic fibroblasts derived from mice lacking both copies of the IFN- $\beta$  gene, implying that fibroblasts depend upon IFN receptor activation by IFN- $\beta$  for IFN- $\alpha$  production (Erlandsson *et al.*, 1998). It is thought that IFN- $\beta$  works by inducing the synthesis of IRF-7, which, following activation by virus infection, leads to stimulation of IFN- $\alpha$  transcription (Au *et al.*, 1998; Marie *et al.*, 1998; Sato *et al.*, 1998a; Yeow *et al.*, 2000). IFN- $\alpha$  is also induced in leukocytes by virus infection. The induction mechanism is poorly characterized in the case of these cells, but is clearly distinct from induction in fibroblasts, since IFN- $\beta$  production is not required (Erlandsson *et al.*, 1998).

IFN- $\gamma$  is produced by Th1 CD4<sup>+</sup> helper T cells and by nearly all CD8<sup>+</sup> cells, as a result of transcriptional activation induced by exposure to antigen-presenting cells (reviewed in Young, 1996). In naive and memory CD4<sup>+</sup> T cells, the IFN- $\gamma$

promoter is under the control of two distinct regulatory elements (proximal and distal; Aune *et al.*, 1997). In contrast, only the distal element is activated in CD8<sup>+</sup> cells, leading to a significantly weaker response than that seen in CD4<sup>+</sup> cells. The proximal element is activated by complexes containing c-Jun and ATF-2, whilst the distal element is activated by GATA-3 and ATF-1 (Penix *et al.*, 1996; Zhang *et al.*, 1998a). The signal transduction mechanisms involved in activating transcription of the IFN- $\gamma$  gene are poorly characterized, but involve the p38 and JNK2 mitogen-activated protein kinase (MAP kinase) pathways (Rincon *et al.*, 1998; Yang *et al.*, 1998; Lu *et al.*, 1999). IFN- $\gamma$  production in response to antigen stimulation is enhanced markedly by IL-12 or IL-18, cytokines produced by activated antigen-presenting cells (reviewed in Okamura *et al.*, 1998). Although neither IL-12 nor IL-18 alone can stimulate IFN- $\gamma$  production significantly in unstimulated T cells, together these cytokines can stimulate IFN- $\gamma$  production in an antigen-independent manner (Tominaga *et al.*, 2000). The molecular




Fig. 3. Signalling pathways activated by IFN- $\alpha/\beta$  and IFN- $\gamma$ . The biological activities of IFNs are initiated by binding to their cognate receptors. This leads to the activation of receptor-associated tyrosine kinases, as discussed in the text. These kinases phosphorylate members of the STAT family of transcription factors, which can enter the nucleus and, either on their own or in combination with p48, bind to the promoters of target genes and bring about gene-specific transcriptional activation. See text for details.

basis of this is unknown, but may involve activation of STAT4 by IL-12 and NF- $\kappa$ B by IL-18, and it may also involve an up-regulation of the IL-18 receptor by IL-12 (Yoshimoto *et al.*, 1998). IFN- $\gamma$  is also produced by activated NK cells in an antigen-independent manner and this is also dependent on IL-12 production by antigen-presenting cells and is stimulated by IL-18 (Singh *et al.*, 2000).

## 2. Signal transduction in response to IFNs

The biological activities of IFNs are initiated by the binding of IFN- $\alpha/\beta$  and IFN- $\gamma$  to their cognate receptors on the surface of cells, which results in the activation of distinct but related signalling pathways, known as the Jak/STAT pathways (reviewed in Stark *et al.*, 1998; summarized in Fig. 3). The ultimate outcome of this signalling is the activation of transcription of target genes that are normally expressed at low levels or are quiescent. The upstream regulatory sequences of most IFN- $\alpha/\beta$ -inducible genes contain a variation of the consensus sequence [GAAAN(N)GAAA] called the ISRE, whilst the upstream regulatory regions of IFN- $\gamma$ -inducible

genes contain a unique element called the gamma activation sequence (GAS), which contains the consensus sequence TTNCNNNA.

The IFN- $\alpha/\beta$  receptor is composed of two major subunits, IFNAR1 and IFNAR2 (reviewed in Mogensen *et al.*, 1999). Prior to stimulation, the cytoplasmic domains of IFNAR1 and IFNAR2 are respectively associated with the 'Janus' tyrosine kinases Tyk2 (Colamonici *et al.*, 1994) and Jak1 (Novick *et al.*, 1994). IFNAR2 is also associated with the 'signal transducer and activator of transcription' (STAT) molecule STAT2 (Li *et al.*, 1997). On IFN- $\alpha/\beta$  binding, IFNAR1 and IFNAR2 associate, facilitating the transphosphorylation and activation of Tyk2 and Jak1 (Novick *et al.*, 1994). Tyk2 then phosphorylates the tyrosine at position 466 (Tyr<sup>466</sup>) on IFNAR1 (Colamonici *et al.*, 1994), creating a new docking site for STAT2 through the latter's SH2 domain (Yan *et al.*, 1996). STAT2 is then phosphorylated by Tyk2 at Tyr<sup>690</sup> and serves as a platform (Leung *et al.*, 1995; Qureshi *et al.*, 1996) for the recruitment of STAT1 (also through its SH2 domain), which is subsequently phosphorylated on Tyr<sup>701</sup> (Shuai *et al.*, 1993). The phosphorylated STAT1/STAT2 heterodimers thus formed



dissociate from the receptor and are translocated to the nucleus through an unknown mechanism, where they associate with the DNA-binding protein p48 (Veals *et al.*, 1992) to form a heterotrimeric complex called ISGF3, which binds the ISRE of IFN- $\alpha/\beta$ -responsive genes. p48 is a member of the IRF family and is sometimes referred to as IRF-9; it should be stressed that, like the IFN- $\beta$  promoter element PRD I, the ISRE sequence can also be bound by other members of the IRF family, notably IRF-1 and IRF-2, and this may have profound biological consequences (see below).

IFN- $\gamma$  receptors are composed of at least two major polypeptides, IFNGR1 and IFNGR2 (reviewed in Bach *et al.*, 1997). In unstimulated cells, IFNGR1 and IFNGR2 do not pre-associate strongly with one another (Bach *et al.*, 1996), but their intracellular domains specifically associate with the Janus kinases Jak1 and Jak2, respectively (Kotenko *et al.*, 1995; Sakatsume *et al.*, 1995; Bach *et al.*, 1996; Kaplan *et al.*, 1996). Binding of the dimeric IFN- $\gamma$  to the receptor triggers receptor dimerization, which brings Jak1 and Jak2 molecules on adjacent receptor molecules into close proximity (Greenlund *et al.*, 1994, 1995; Igarashi *et al.*, 1994; Bach *et al.*, 1996); Jak2 is thus activated and in turn activates Jak1 by transphosphorylation (Briscoe *et al.*, 1996). The activated Jaks then phosphorylate a tyrosine-containing sequence near the C terminus of IFNGR1 (Tyr<sup>440</sup>–Tyr<sup>444</sup>), thereby forming paired binding sites for STAT1 that interact through their SH2 domains (Greenlund *et al.*, 1994, 1995; Igarashi *et al.*, 1994) and are phosphorylated at Tyr<sup>701</sup>, near the C terminus (Shuai *et al.*, 1993, 1994; Greenlund *et al.*, 1994; Heim *et al.*, 1995). The phosphorylated STAT1 proteins dissociate from the receptor and form a homodimer, through SH2 domain–tyrosine phosphate recognition, which translocates to the nucleus through a poorly characterized mechanism (Sekimoto *et al.*, 1996). Active STAT1 homodimers, also called gamma-activated factor (GAF), bind to specific GAS elements of IFN- $\gamma$ -inducible genes (reviewed by Stark *et al.*, 1998) and stimulate transcription. IFN- $\alpha/\beta$  can also induce the formation of STAT1 homodimers, albeit less efficiently than IFN- $\gamma$  (Haque & Williams, 1994), although the mechanism whereby STAT1 homodimers are activated by IFN- $\alpha/\beta$  remains obscure.

The transactivation function of STAT1 depends upon phosphorylation of Ser<sup>727</sup> (Wen *et al.*, 1995) by a kinase with MAP-like specificity. The identity of this kinase remains controversial, although it may differ between cell types. Thus, p38 kinase has been shown to be important for Ser<sup>727</sup> phosphorylation in response to IFN- $\alpha/\beta$  and IFN- $\gamma$  in mouse fibroblasts (Goh *et al.*, 1999) but not in response to IFN- $\gamma$  in macrophages (Kovarik *et al.*, 1999). Furthermore, the protein tyrosine kinase Pyk2 has recently been shown to be a critical mediator of the Jak-dependent activation of Ser<sup>727</sup> phosphorylation of STAT1 in IFN- $\gamma$ , but not IFN- $\alpha/\beta$ , signalling (Takaoka *et al.*, 1999). It has also recently been shown that PKR plays a role in Ser<sup>727</sup> phosphorylation (Ramana *et al.*, 2000), but this is unlikely to be direct. The role of Ser<sup>727</sup>

phosphorylation is to facilitate interaction of STAT1 with the basal transcriptional machinery. Recent studies have revealed important connections between STAT1 and the CREB-binding protein (CBP)/p300 transcription factors. The CBP/p300 family of transcription factors potentiate the activity of several groups of transcription factors (reviewed in Janknecht & Hunter, 1996). Both the C- and N-terminal domains of STAT1 have been shown to bind CBP/p300 (Zhang *et al.*, 1996). STAT1 also interacts with the chromatin-associated protein MCM5 in a Ser<sup>727</sup>-dependent manner (Zhang *et al.*, 1998*b*) and with Nmi, a protein that acts to enhance the association between STAT1 and CBP/p300 (Zhu *et al.*, 1999). Although STAT2 does not contain a MAP kinase consensus site and is not known to be serine-phosphorylated in response to IFN, it also binds CBP/p300 and facilitates interaction with the basal transcriptional machinery (Bhattacharya *et al.*, 1996).

A second form of STAT1 (STAT1 $\beta$ ) can be derived by differential splicing. STAT1 $\beta$  contains the tyrosine at position 701 and is recruited to the receptor complex, becomes tyrosine-phosphorylated and binds DNA. However, STAT1 $\beta$  differs from the predominant form of STAT1 (STAT1 $\alpha$ ) by lacking the C-terminal 38 amino acids that include Ser<sup>727</sup> and, thus, it cannot activate transcription (Schindler *et al.*, 1992; Shuai *et al.*, 1993). The function of STAT1 $\beta$  is not clear. Although it can become incorporated into ISGF3 complexes that retain their transcriptional activation potential as a result of STAT2 function (Muller *et al.*, 1993), the consequences of a potential STAT1 $\alpha$ /STAT1 $\beta$  heterodimer have not been established, but these might well down-regulate transcription.

Recently, several other proteins have been identified that may also be required for IFN signalling. For example, the tyrosine phosphatase SHP-2, which pre-associates with IFNAR1, is phosphorylated in response to IFN- $\alpha/\beta$  and, in transfection experiments, a dominant-negative form of SHP-2 inhibits the IFN- $\alpha/\beta$ -induced expression of a reporter gene (David *et al.*, 1996). IFN- $\alpha/\beta$  treatment also induces the phosphorylation and activation of cytosolic phospholipase A2 (CPLA2), an event that requires Jak1 and the p38 MAP kinase (Goh *et al.*, 1999). The demonstration that CPLA2 inhibitors can block the expression of ISRE-containing genes induced by IFN- $\alpha/\beta$  implies that CPLA2 also plays a role in the transactivation of ISRE-containing genes (Hannigan & Williams, 1991; Flati *et al.*, 1996).

As discussed above, other members of the IRF family can bind ISRE sequences and our understanding of IFN-mediated signal transduction is complicated by the fact that some of these IRF proteins are inducible by IFNs. Thus, both IFN- $\alpha/\beta$  and IFN- $\gamma$  can induce IRF-1, which can then serve to sustain expression of genes that contain ISREs. Indeed, IRF-1-dependent gene expression in response to IFNs has been observed in a number of cases (see for example Kimura *et al.*, 1994; Chatterjee-Kishore *et al.*, 1998; Kano *et al.*, 1999; Salkowski *et al.*, 1999; Karlsen *et al.*, 2000). This can give rise to complex patterns of gene expression whereby, for

example, IFN- $\gamma$  can induce the synthesis of genes that lack GAS sites via the induction of IRF-1 (see for example Lechleitner *et al.*, 1998; Foss & Prydz, 1999; Piskurich *et al.*, 1999).

In contrast to the mechanism of IFN signal transduction, little is known about the mechanism of signal attenuation. Several IRF proteins, including IRF-2 (Harada *et al.*, 1989) and the IFN-consensus sequence-binding protein (ICSBP, also called IRF-8; Nelson *et al.*, 1993), are known to bind ISREs and negatively regulate expression, and may help to prevent expression in the absence of IFN or down-regulate the induced response. IFN-induced proteins play a major role in signal attenuation, since protein synthesis inhibitors prolong the transcription of IFN-induced genes (Friedman *et al.*, 1984; Larner *et al.*, 1986). One group of proteins with the potential to fulfil this role is the SOCS/JAB/SSI family, which are inducible by IFN- $\gamma$  and several other cytokines and bind to and inhibit activated Jaks, leading to signal down-regulation (Endo *et al.*, 1997; Naka *et al.*, 1997; Starr *et al.*, 1997; Starr & Hilton, 1999).

Activation by STAT1 is usually transient, as a result of dephosphorylation by a tyrosine phosphatase (Igarashi *et al.*, 1993; Haque *et al.*, 1995). However, it is not known whether the phosphatase acts on phosphorylated STATs in the nucleus or on phosphorylated Jaks or receptor subunits at the plasma membrane. The tyrosine phosphatase SHP-1 has been shown to be associated reversibly with IFNAR-1 after IFN- $\alpha$  stimulation (David *et al.*, 1995) and Jak1 and STAT1 phosphorylation is increased significantly in macrophages isolated from mice that lack SHP-1 activity compared with normal control macrophages (Haque & Williams, 1998), suggesting that SHP-1 may play a role in signal attenuation. In addition to down-regulation by dephosphorylation, STAT1 is turned over by a mechanism involving proteasome-mediated degradation, but there is no evidence that this process is important in the regulation of STAT1 function (Kim & Maniatis, 1996).

### 3. The antiviral response

The best-characterized IFN-inducible components of the antiviral response are PKR and the 2'-5' oligoadenylate synthetases, although it is clear that other factors may be involved, especially molecules that regulate the cell cycle or cell death and thereby limit the extent of virus replication. In many cases, IFN-inducible enzymes are inactive until exposed to virus infection, thus ensuring that uninfected cells do not suffer undue trauma. It is thought that the virus co-factor that activates these IFN-inducible enzymes is dsRNA (reviewed in Jacobs & Langland, 1996).

(i) **dsRNA-dependent protein kinase R (PKR).** The IFN-inducible PKR is a serine/threonine kinase with multiple functions in control of transcription and translation (reviewed in Clemens & Elia, 1997). The PKR protein has two well-characterized domains, an N-terminal regulatory domain that contains the dsRNA-binding site and a C-terminal catalytic domain that

contains all of the conserved motifs for protein kinase activity (Meurs *et al.*, 1990). PKR is normally inactive, but is activated by binding to dsRNA or other polyanions (Meurs *et al.*, 1990; Katze *et al.*, 1991; George *et al.*, 1996), whereupon it undergoes a conformational change that leads to the unmasking of the catalytic domain. The active form of PKR is postulated to be a dimer, with two PKR molecules binding one molecule of dsRNA; the juxtaposed PKR molecules transphosphorylate each other on several serines and threonines. PKR activation is decreased when large amounts of dsRNA are present, due to saturation of dsRNA-binding sites and a shift in the equilibrium towards monomers. There are no sequence requirements for the dsRNA, although some RNAs are more potent activators than others. However, there are size requirements, with at least 50 base pairs of duplex being necessary for activation (reviewed in Robertson & Mathews, 1996).

Activated PKR has a number of important cell-regulatory activities. Firstly, it phosphorylates the  $\alpha$  subunit of the eukaryotic translation initiation factor eIF2 and prevents the recycling of initiation factors (Meurs *et al.*, 1992; reviewed in Clemens & Elia, 1997). In the initial step of translation, the initiator Met-tRNA is recruited to the 40S ribosomal subunit via an interaction with GTP-bound eIF2 (which consists of three subunits,  $\alpha$ ,  $\beta$  and  $\gamma$ ). This complex then interacts with mRNA, other initiation factors and the large ribosomal subunit to form a pre-initiation complex, with subsequent hydrolysis of the GTP molecule bound to eIF2 and release of GDP-bound eIF2. In order to participate in another round of translational initiation, the GDP bound to eIF2 must be exchanged for GTP, a reaction that is catalysed by the guanine exchange factor, eIF2B. Phosphorylated eIF2 $\alpha$  interacts strongly with eIF2B and traps it such that it cannot mediate the recycling of eIF2 (Ramaiah *et al.*, 1994; reviewed by Clemens & Elia, 1997). Since eIF2B is present in limiting amounts, translation is inhibited.

PKR also plays a role in mediating signal transduction in response to dsRNA and other ligands (reviewed in Williams, 1999). For example, the transcription factor NF- $\kappa$ B, which is essential for mediating induction of the IFN- $\beta$  gene, is activated by PKR in response to dsRNA (see section 1). PKR has also been proposed to influence the activity of the transcription factors STAT1 (Wong *et al.*, 1997; Ramana *et al.*, 2000), IRF-1 (Kumar *et al.*, 1997) and p53 (Cuddihy *et al.*, 1999*a, b*), although the details of the activation events remain to be clarified. The elevated levels of PKR that would be found in a cell exposed to IFN would cause an enhancement of these signal transduction events, which may help to accelerate virus clearance. For example, enhanced activation of NF- $\kappa$ B activation would lead to increased cytokine, chemokine and MHC class I presentation.

PKR also aids in the clearance of virus infection by mediating apoptosis. It has been shown that dsRNA (and thus virus infection) can trigger apoptosis directly (Der *et al.*, 1997; King & Goodbourn, 1998; Tanaka *et al.*, 1998) and there

is considerable evidence that this effect works through PKR (Takizawa *et al.*, 1996; Der *et al.*, 1997; reviewed in Jagus *et al.*, 1999; Tan & Katze, 1999), although PKR-independent mechanisms also operate for some viruses (Balachandran *et al.*, 2000). The downstream targets for PKR-mediated apoptosis remain to be identified, but overexpression of PKR has been shown to induce apoptosis through a Bcl2- and caspase-dependent mechanism (Lee *et al.*, 1997). Intriguingly, although mice with a targeted knockout of the dsRNA-binding domain of PKR are sensitive to virus-induced apoptosis (Yang *et al.*, 1995), mice with a targeted knockout of the PKR catalytic domain are not (Abraham *et al.*, 1999).

PKR also plays a role in mediating the apoptotic effects of dsRNA in an indirect manner. In this case, effects on protein synthesis are important (Srivastava *et al.*, 1998; Gil *et al.*, 1999), as are effects on the transcription factor NF- $\kappa$ B (Gil *et al.*, 1999). Exposure of cells to dsRNA also enhances apoptosis by inducing the synthesis of Fas (Takizawa *et al.*, 1995; Balachandran *et al.*, 1998; Fujimoto *et al.*, 1998) and Fas receptor (Fujimoto *et al.*, 1998) in a manner that depends upon PKR (Balachandran *et al.*, 1998). Finally, the apoptotic effects of TNF on promonocytic U937 cells require p53 to ensure a response to activated PKR (Yeung *et al.*, 1996).

Although there is abundant evidence that PKR plays a major role in regulating virus infection, PKR is not sufficient to mediate the full antiviral response. Thus, mice with homozygous disruptions of the PKR gene (Yang *et al.*, 1995; Abraham *et al.*, 1999) still show resistance to virus infection, although the wild-type but not the PKR-deficient animals are protected to some extent by injection of dsRNA at virus doses that are normally lethal (Yang *et al.*, 1995).

(ii) **The 2'-5' oligoadenylate synthetase system.** 2'-5' oligoadenylate synthetases are a group of enzymes that are induced by IFNs in mammalian cells and catalyse the synthesis from ATP of oligomers (three to five units) of adenosine linked by phosphodiester bonds in the unusual conformation of 2' to 5' (2'5'A; Kerr & Brown, 1978). The 2'5'A molecules bind with high affinity to endoribonuclease L (RNase L) and induce its activation via dimerization. Activated RNase L catalyses the cleavage of single-stranded RNA including mRNA, thereby leading to inhibition of protein synthesis (reviewed in Silverman, 1997). It has recently been demonstrated that RNase L also cleaves 28S ribosomal RNA in a site-specific manner, leading to ribosomal inactivation and thus translational inhibition (Iordanov *et al.*, 2000). Since 2'5'A is highly labile, the activation of RNase L depends upon locally activated 2'-5' oligoadenylate synthetase within the cell, thus ensuring that virus transcripts are destroyed preferentially over cellular mRNAs, since they are in the vicinity of the activator (viral dsRNA; Nilsen & Baglioni, 1979).

The 2'-5' oligoadenylate synthetase/RNase L system has been suggested to play a role in the antiviral effects of IFN- $\alpha/\beta$  against vaccinia virus, reovirus and encephalomyocarditis virus

(reviewed in Silverman & Cirino, 1997) and antiviral effects of IFN- $\alpha$  are indeed impaired in RNase L<sup>-/-</sup> mice (Zhou *et al.*, 1997). RNase L may also play a role in apoptosis, since RNase L<sup>-/-</sup> mice show defects in apoptosis in several tissues (Zhou *et al.*, 1997) whilst activation of RNase L induces apoptosis (Diaz-Guerra *et al.*, 1997). Although the exact role of RNase L in apoptosis is not clear, it seems likely that the 2'-5' oligoadenylate synthetase/RNase L system may contribute to the antiviral activity of IFN by inducing apoptosis of infected cells (Zhou *et al.*, 1997; Castelli *et al.*, 1998a, b).

(iii) **Alternative antiviral pathways.** The IFN-inducible Mx proteins are highly conserved, large GTPases with homology to dynamin and have been found in all vertebrate species examined so far, including mammals, birds and fish (reviewed in Staeheli *et al.*, 1993; Arnheiter *et al.*, 1995). Mx proteins interfere with virus replication, probably by inhibiting the trafficking or activity of virus polymerases (Stranden *et al.*, 1993), thereby impairing the growth of a wide range of RNA viruses at the level of virus transcription and at other steps in the virus life-cycle. The murine nuclear protein Mx1 has been shown to suppress the growth of members of the *Orthomyxoviridae* (Staeheli *et al.*, 1986, 1988; Haller *et al.*, 1995). The human cytoplasmic protein MxA inhibits the growth of members of several RNA families, including the *Orthomyxoviridae* (Pavlovic *et al.*, 1990, 1992; Frese *et al.*, 1995, 1997), *Paramyxoviridae* (Schneider-Schaulies *et al.*, 1994; Zhao *et al.*, 1996), *Rhabdoviridae* (Pavlovic *et al.*, 1990), *Bunyaviridae* (Frese *et al.*, 1996; Kanerva *et al.*, 1996) and *Togaviridae* (Landis *et al.*, 1998). Mutant forms of Mx proteins lacking the ability to bind or hydrolyse GTP fail to suppress virus replication. Hefti *et al.* (1999) have analysed the behaviour of transgenic mice that constitutively express the human MxA gene in a mouse background lacking the IFN- $\alpha/\beta$  receptor and have shown that the MxA protein protects mice against Thogoto virus, La Crosse virus and Semliki Forest virus.

Recent studies involving the generation of mice that are triply deficient in RNase L, PKR and Mx1 indicate that there are additional antiviral effects of IFNs (Zhou *et al.*, 1999). Other factors that clearly play a role in the IFN-induced antiviral response are caspases (see below) and the dsRNA-dependent adenosine deaminase (ADAR). The enzyme ADAR recognizes dsRNA as a substrate and unwinds it as a result of systematically replacing adenosines with inosine (Bass *et al.*, 1989; Polson & Bass, 1994; O'Connell *et al.*, 1995; Patterson *et al.*, 1995). Since many viral RNAs go through a dsRNA-based replicative intermediate, this has the effect of being mutagenic, and there are several reports of genomic substitutions consistent with this activity (Bass *et al.*, 1989; Cattaneo, 1994; Casey & Gerin, 1995; Hajjar & Linal, 1995; Horikami & Moyer, 1995; Polson *et al.*, 1996). It has also been suggested that an inosine-specific ribonuclease could act in concert with ADAR to destroy modified viral RNAs (Scadden & Smith, 1997).



(iv) **Antiproliferative activities of IFNs.** IFNs can inhibit cell growth and thereby inhibit the replication of some viruses. However, the sensitivity of cells to the antiproliferative effects of IFNs is very cell-type dependent. For example, growth of the Daudi B cell line is arrested completely by as little as 1 unit/ml IFN- $\alpha/\beta$ , whereas many cell types are largely unresponsive at any dose tested. Because of the potential clinical importance of the cytostatic properties of IFN, the negative regulation of growth has been studied intensively and a number of aspects of this process have been described. There is evidence to support a role for PKR and RNase L in the antiproliferative functions of IFNs. The amount of PKR can vary according to the state of growth of mammalian cells in culture and this appears to correlate with the level of eIF2 $\alpha$  phosphorylation (reviewed in Jaramillo *et al.*, 1995), suggesting that, even in the absence of viral dsRNA, PKR can exhibit residual activity, presumably due to the presence of a cellular activator. Additionally, overexpression of PKR is growth suppressive and/or toxic in insect, mammalian and yeast cells (Koromilas *et al.*, 1992; Chong *et al.*, 1992; Dever *et al.*, 1993), an effect which can also be shown to be due to eIF2 $\alpha$  phosphorylation. Overexpression of the 40 kDa form of 2'-5' oligoadenylate synthetase has been shown to reduce growth rates of transfected cells (Chebath *et al.*, 1987; Rysiecki *et al.*, 1989; Coccia *et al.*, 1990) and expression of a dominant-negative mutant of RNase L in murine SVT2 cells inhibited the antiproliferative effect of IFN on these cells (Hassel *et al.*, 1993).

IFNs can also exert negative regulation of the cell cycle at a more direct level. IFNs have been shown to up-regulate specifically the levels of the cyclin-dependent kinase inhibitor p21 (Chin *et al.*, 1996; Subramaniam & Johnson, 1997; Subramaniam *et al.*, 1998), which plays a crucial role in the progression from G<sub>1</sub> into S phase (reviewed in Harper *et al.*, 1993; Gartel *et al.*, 1996). When p21 levels are elevated, cyclin-dependent kinase activity is turned off and consequently the phosphorylation of the retinoblastoma gene product (pRb) and the related pocket proteins is suppressed (Sangfelt *et al.*, 1999). Since hypophosphorylated pRb and the related pocket proteins interact strongly with the E2F family of transcription factors, there is a consequent increase in the pRB-/pocket protein-bound E2F complexes (Iwase *et al.*, 1997; Kirch *et al.*, 1997; Furukawa *et al.*, 1999). The significance of this is that free E2F is required for the transcription of many genes that are needed for transition from G<sub>1</sub> to S phase and thus the elevation of pRB-/pocket protein-bound E2F complexes results in a block to the cell cycle.

Another major IFN-inducible activity that can act as a potent repressor of the cell cycle is the p202 gene product and related members of its '200 family' (Kingsmore *et al.*, 1989; Lembo *et al.*, 1995; Gutterman & Choubey, 1999). The p202 product can bind both hypophosphorylated pRb (Choubey & Lengyel, 1995) and members of the E2F transcription family (Choubey *et al.*, 1996; Choubey & Gutterman, 1997) as well as complexes containing both. The

complex between E2F and p202 is unable to bind DNA and hence there is a loss of stimulation of transcription of genes important for the G<sub>1</sub>-S transition. Since the p202 protein also contains a transcriptional repression domain (Johnstone *et al.*, 1998), any recruitment to DNA would also shut down gene expression. Finally, IFNs have been shown recently to down-regulate directly the transcription of c-myc, an essential gene product that is required to drive cell cycle progression (Ramana *et al.*, 2000).

(v) **Control of apoptosis.** IFNs, like other cytokines, can have either pro- or anti-apoptotic activities depending on various factors including the state of cell differentiation. For example, IFN- $\gamma$  induces apoptosis of murine pre-B cells but inhibits apoptosis of chronic lymphocytic leukaemia cells (Buschle *et al.*, 1993; Grawunder *et al.*, 1993; Rojas *et al.*, 1996). However, when a cell is infected with a virus, a major function of IFN is to ensure that the cell is triggered to undergo apoptosis (Tanaka *et al.*, 1998). IFN appears to do this by inducing a pro-apoptotic state in uninfected cells (reviewed in Schindler, 1998). As discussed above, IFN-induction of PKR and the 2'5'A system plays a major role in the apoptosis response. However, IFN has also been demonstrated to induce caspase 1 (Chin *et al.*, 1997), caspase 3 (Subramaniam *et al.*, 1998) and caspase 8 (Balachandran *et al.*, 2000) and thus to enhance the sensitivity of cells to virus-induced apoptosis. IFN- $\gamma$  has also been shown to influence the sensitivity to apoptosis by inducing both Fas and Fas ligand (Xu *et al.*, 1998).

(vi) **Immunomodulatory functions of IFNs.** Nearly all phases of innate and adaptive immune responses are affected profoundly by IFNs. All IFN family members share the ability to enhance the expression of MHC class I proteins and thereby to promote CD8<sup>+</sup> T cell responses (reviewed in Boehm *et al.*, 1997). In contrast, only IFN- $\gamma$  is capable of inducing the expression of MHC class II proteins, thus promoting CD4<sup>+</sup> T cell responses. IFNs play an important role in antigen processing by regulating the expression of many proteins involved in the generation of antigenic peptides to be displayed in association with MHC class I proteins. IFN- $\gamma$  modifies the activity of proteasomes (reviewed in York & Rock, 1996) such that they enhance the generation of peptides that bind class I MHC proteins. In unstimulated cells, the proteasome contains the three enzymatic subunits x, y and z. However, following IFN- $\gamma$  treatment of cells, the transcription of the x, y and z genes is decreased and the transcription of three additional genes encoding enzymatic proteasome subunits LMP2, LMP7 and MECL1 is increased. This results in the formation of proteasomes with different substrate specificities, thereby altering the types of peptide produced and subsequently presented to the immune system. IFN- $\gamma$  also increases the expression of TAP1 and TAP2, which are involved in the transfer of peptides (generated by the proteasome) from the cytoplasm into the endoplasmic reticulum to bind nascent MHC class I proteins (Trowsdale *et al.*, 1990; Epperson *et al.*,



1992). Thus, IFNs enhance immunogenicity by increasing the repertoire and quantity of peptides displayed to CD8<sup>+</sup> T cells.

IFN- $\gamma$  also plays an important role in regulating the balance between Th1 and Th2 cells. Firstly, it increases the synthesis of IL-12 in antigen-presenting cells (Dighe *et al.*, 1995; Flesch *et al.*, 1995; Murphy *et al.*, 1995). IL-12 is the primary effector that drives developing CD4<sup>+</sup> T cells to become Th1 cells (Hsieh *et al.*, 1993; Trinchieri, 1995). Secondly, IFN- $\gamma$  prevents the development of Th2 cells by inhibiting the production of IL-4, which is required for Th2 cell formation (Gajewski & Fitch, 1988; Szabo *et al.*, 1995). IFN- $\gamma$  also plays an important role in macrophage activation (Adams & Hamilton, 1984; Buchmeier & Schreiber, 1985; Dalton *et al.*, 1993; Huang *et al.*, 1993). Once activated, macrophages use a variety of IFN- $\gamma$ -induced mechanisms to kill microbial targets. The most important of these mechanisms involve the production of reactive oxygen and reactive nitrogen intermediates. Reactive oxygen intermediates are generated as products of the enzyme NADPH oxidase, the assembly of which is induced by IFN- $\gamma$ . Reactive nitrogen intermediates, especially nitric oxide (NO), are generated in murine macrophages as a result of the IFN- $\gamma$ -dependent transcription of the gene encoding the inducible form of nitric oxide synthase (iNOS), which catalyses NO formation (MacMicking *et al.*, 1997).

In addition to affecting humoral immunity indirectly by regulating the development of specific T helper cell subsets, IFNs can have direct effects on B cells by regulating development and proliferation, immunoglobulin (Ig) secretion and Ig heavy-chain switching. Since different Ig isotypes promote distinct effector functions in the host, IFNs can facilitate interactions between the humoral and cellular effector limbs of the immune response and increase the host defence against certain bacteria and viruses by selectively enhancing the production of certain Ig isotypes while inhibiting the production of others (Snapper & Paul, 1987; Snapper *et al.*, 1988, 1992).

A major immunomodulatory function of IFN- $\alpha/\beta$  is to enhance the cytotoxicity of NK cells (reviewed in Reiter, 1993; Biron *et al.*, 1999) by up-regulating the levels of perforins (Mori *et al.*, 1998; Kaser *et al.*, 1999). IFN- $\alpha/\beta$  also acts to stimulate the proliferation of NK cells to a limited degree, apparently via the induction of IL-15 from monocytes/macrophages (Ogasawara *et al.*, 1998; Fawaz *et al.*, 1999; Gosselin *et al.*, 1999; Sprent *et al.*, 1999). NK cells also synthesize and secrete IFN- $\gamma$  in response to a combination of IL-12 and IL-15, which are released from infected monocytes/macrophages (Doherty *et al.*, 1996; Fehniger *et al.*, 1999). However, IFN- $\alpha/\beta$  blocks the production of IL-12 by infected monocytes (reviewed in Biron *et al.*, 1999) and thus prevents NK cells from producing IFN- $\gamma$ . The biological reasons, if any, behind this are unclear. Finally, IFN- $\alpha/\beta$ s also play a role in stimulating the adaptive responses; IFN-induced IL-15 can stimulate the division of memory T cells (Tough *et al.*, 1996; Zhang *et al.*, 1998c; reviewed in Tough *et al.*, 1999; Sprent

*et al.*, 1999), whilst IFN- $\alpha/\beta$  appears to be able to promote the survival of activated T cells directly (Marrack *et al.*, 1999).

## B. Virus countermeasures to the IFN response

### 4. Inhibition of IFN production

Viruses vary considerably in their ability to induce IFN. This may simply reflect the amounts of dsRNA produced during their replication cycles (in general, DNA viruses produce less dsRNA than RNA viruses and are therefore less potent inducers of IFN; reviewed in Jacobs & Langland, 1996) or it may reflect the fact that many viruses produce dsRNA-binding proteins as part of their life-cycle. The sequestration of dsRNA could inhibit the induction of IFN- $\alpha/\beta$  and might also act to minimize the dsRNA-dependent activation of antiviral gene products like PKR, 2'-5' oligoadenylate synthetase and ADAR, as well as dsRNA-dependent apoptosis. For example, the reovirus major outer capsid protein  $\sigma 3$  is a dsRNA-binding protein (Lloyd & Shatkin, 1992; Yue & Shatkin, 1997; reviewed in Jacobs & Langland, 1998), as is the  $\sigma A$  protein of avian reovirus (Martinez-Costas *et al.*, 2000). Reovirus strains vary significantly in their ability to induce IFN- $\alpha/\beta$  (reviewed in Samuel, 1998); although this has not yet been shown to be a function of variation in the  $\sigma 3$  protein, it is interesting to note that strain differences in IFN sensitivity have been linked to differences in dsRNA affinity of the  $\sigma 3$  protein (Bergeron *et al.*, 1998). The multifunctional NS1 protein of influenza virus (Lu *et al.*, 1995), the E3L protein of vaccinia virus (Chang *et al.*, 1992) and products of the NSP3 gene of porcine rotaviruses (Langland *et al.*, 1994) also bind dsRNA and a number of other viruses that have been reported to block IFN production at the transcriptional level may also do so by sequestering dsRNA [e.g. the core antigen of hepatitis B virus (HBV); Twu & Schloemer, 1989; Whitten *et al.*, 1991]. The sequestration of dsRNA by viral proteins might have a wider role in protecting the virus from antiviral mechanisms; dsRNA-activated PKR can activate NF- $\kappa$ B and induce the synthesis of immunomodulatory genes in addition to IFN- $\alpha/\beta$ .

Since the activation of NF- $\kappa$ B by infection is a key trigger to inducing IFN- $\alpha/\beta$  transcription and other immune responses, it would perhaps not be surprising to find that many viruses encoded inhibitors of NF- $\kappa$ B activation or function. Indeed, African swine fever virus (ASFV) encodes a homologue of I $\kappa$ B that inhibits the activity of NF- $\kappa$ B (Powell *et al.*, 1996; Revilla *et al.*, 1998). However, it is well established that NF- $\kappa$ B, as well as inducing proinflammatory cytokines, also induces anti-apoptotic genes (Liu *et al.*, 1996; Wu *et al.*, 1996; Wang *et al.*, 1996; Van Antwerp *et al.*, 1996; reviewed in Van Antwerp *et al.*, 1998; Foo & Nolan, 1999) and any virus that blocks NF- $\kappa$ B activation may leave itself susceptible to enhanced induction of apoptosis. Interestingly, ASFV infections are indeed characterized by a significant degree of apoptosis (Oura *et al.*, 1998). The increased risk of apoptosis associated with inhibition of

NF- $\kappa$ B may be circumvented by viral gene products that act to block apoptosis; such gene products are widespread (reviewed in Cuff & Ruby, 1996; Gillet & Brun, 1996).

Another major strategy for blocking IFN- $\alpha/\beta$  production would be to target the activities of the IRF transcription factors that bind to the PRD I region of the IFN- $\beta$  promoter. Intriguingly, the E6 protein of human papillomavirus type 16 (HPV-16) binds IRF-3 and can inhibit its virus-induced transcriptional activation function (Ronco *et al.*, 1998). However, induction of IFN- $\beta$  is not blocked completely by the E6 protein, suggesting that other cellular factors can substitute functionally for IRF-3, and indeed, as discussed above, there are several lines of evidence consistent with this hypothesis. The potential substitutes for IRF-3 include IRF-1 (Miyamoto *et al.*, 1988; Fujita *et al.*, 1989a; Watanabe *et al.*, 1991; Reis *et al.*, 1992; Matsuyama *et al.*, 1993) and ISGF3 (Yoneyama *et al.*, 1996), but these factors can themselves be targeted by virus functions. For example, IRF-1 is targeted by the K9 ORF gene product of human herpesvirus-8 (HHV-8) (Zimring *et al.*, 1998), whilst the E7 protein of HPV-16 interacts with the p48 subunit of ISGF3 and prevents binding to DNA (Barnard & McMillan, 1999). Perhaps the plethora of factors that can bind to the PRD I region of the IFN- $\beta$  promoter reflects a need of the cell to be able to circumvent virus blockades.

In addition to specific transcription factor blocks, viruses may inhibit the production of IFN by generally down-regulating host mRNA production or protein synthesis, and there is some evidence that these apparently non-specific effects can affect virus pathogenicity. For example, mutation in the gene encoding the matrix M protein of vesicular stomatitis virus (which in wild-type virus causes a general inhibition of host-cell transcription) leads to an attenuated virus with efficient IFN- $\beta$ -inducing properties (Ferran & Lucas-Lenard, 1997). Similarly, the foot-and-mouth disease virus L proteinase gene encodes a protein that shuts off host-cell protein synthesis and mutation of this gene is sufficient to generate an attenuated strain that induces elevated levels of IFN- $\alpha/\beta$  (Chinsangaram *et al.*, 1999).

Viruses may also have more subtle and indirect methods for reducing the level of IFN produced. For example, Epstein-Barr virus (EBV) produces a homologue of IL-10 (Hsu *et al.*, 1990). Normally, IL-10 is produced by the Th2 subset of T helper cells and one of its biological functions is to inhibit the ability of monocytes and macrophages to activate Th1 cells by down-regulating the expression of class II MHC molecules. Activated Th1 cells produce a number of cytokines, including IFN- $\gamma$ , that are critical for the induction of classical cell-mediated immune responses, including cytotoxic T lymphocytes. It has therefore been proposed that EBV produces the homologue of IL-10 in order to induce an inappropriate and less-effective immune response against the virus (Bejarano & Masucci, 1998). Similarly, human herpesvirus-6 may up-regulate IL-10, thereby causing immunodysregulation by causing a shift from a Th1 to a Th2 cytokine profile (Arena *et al.*, 1999).

## 5. Inhibition of IFN signalling

There are clear advantages to viruses in having the ability to block IFN signalling. Since there are components in common between signalling pathways, it is possible for a virus to block IFN- $\alpha/\beta$  or IFN- $\gamma$  signalling or both. Using such strategies, not only would the induction of cellular antiviral enzymes, such as PKR, 2'-5' oligoadenylate synthetase and Mx, be inhibited but there would also be no up-regulation of class I MHC molecules within infected cells, making them poorer targets for cytotoxic T cells. Furthermore, virus-infected cells would be resistant to the actions of IFNs regardless of whether the IFNs were produced by infected cells or by activated leukocytes.

Blocking the IFN signalling pathways could occur at several levels and there is accumulating evidence that viruses can block at most, if not all, stages (Table 1). Several poxviruses have been shown to encode soluble IFN-receptor homologues that bind and sequester IFNs, thereby preventing their biological activity. For example, functional IFN- $\gamma$  receptors are secreted by cells infected with rabbit myxoma virus, ectromelia virus, cowpox virus, camelpox virus and vaccinia virus (Upton *et al.*, 1992; Mossman *et al.*, 1995; Alcami & Smith, 1995). Vaccinia virus and most other orthopoxviruses also encode soluble IFN- $\alpha/\beta$  receptor homologues (Symons *et al.*, 1995; Colamonici *et al.*, 1995). It appears that the vIFN- $\alpha/\beta$  receptor of vaccinia virus can also bind to the surface of cells and inhibit IFN activity. Intriguingly, highly attenuated strains of vaccinia virus do not secrete the IFN- $\alpha/\beta$  receptor, consistent with its importance in virus pathogenesis. Interestingly, in terms of virus host range, both the IFN- $\alpha/\beta$  and IFN- $\gamma$  receptor homologues secreted by poxviruses often have a broad species specificity, unlike their cellular counterparts.

Human cytomegalovirus (HCMV) has been shown to disrupt IFN signalling by decreasing the levels of Jak1 and p48 by a mechanism involving the proteasome (Miller *et al.*, 1998, 1999), whereas the T antigen of murine polyomavirus (MPyV) binds to Jak1 thereby blocking the activation of the IFN- $\alpha/\beta$  and IFN- $\gamma$  signalling pathways (Weihs *et al.*, 1998). The STAT and p48 proteins that form part of IFN-inducible transcription complexes are targets for inhibition by several viruses. The V protein of the paramyxovirus simian virus 5 (SV5) targets STAT1 for proteasome-mediated degradation (Didcock *et al.*, 1999b), thereby preventing the formation of ISGF3 and GAF complexes; indeed, at least part of the host range of SV5 appears to be determined by the ability to mediate STAT1 degradation (Didcock *et al.*, 1999a). Surprisingly, whilst mumps virus also probably targets STAT1 for degradation (Yokosawa *et al.*, 1998), human parainfluenza virus 2 (hPIV2) (a virus very closely related to SV5 and mumps) targets STAT2 (Young *et al.*, 2000). As a consequence, whilst SV5 and mumps virus block both IFN- $\alpha/\beta$  and IFN- $\gamma$  signalling, hPIV2 blocks only IFN- $\alpha/\beta$  signalling. Sendai virus (Didcock *et al.*, 1999b; Yokoo *et al.*, 1999) and hPIV3 also block IFN- $\alpha/\beta$  and IFN- $\gamma$  signalling, although there was no evidence with these viruses that either

**Table 1.** Virus inhibition of IFN signalling and IFN-induced transcriptional responses

Virus	Mechanism of action/inhibition
<b>i. Inhibition of IFN binding to cognate receptors</b>	
Poxviruses (many)	Soluble IFN- $\alpha/\beta$ receptor
Poxviruses (many)	Soluble IFN- $\gamma$ receptor
<b>ii. Inhibition of Jak/STAT pathway</b>	
Adenovirus	E1A decreases the levels of STAT1 and p48; sequesters the transcriptional co-activator, CBP/p300, which binds STAT1 and STAT2; interacts directly with STAT1
Ebola virus	Blocks IFN- $\alpha/\beta$ and IFN- $\gamma$ signalling, mechanism unknown
Epstein-Barr virus	EBNA-2 blocks IFN signal transduction, mechanism unknown
Hepatitis C virus	Blocks IFN- $\alpha/\beta$ and IFN- $\gamma$ signalling, mechanism unknown
Human cytomegalovirus	Reduces levels of Jak1 and p48
Human parainfluenza virus type 2	Blocks IFN- $\alpha/\beta$ signalling by targetting STAT2 for degradation
Human parainfluenza virus type 3 and Sendai virus	Block IFN- $\alpha/\beta$ and IFN- $\gamma$ signalling by blocking STAT1 phosphorylation
Human papillomavirus type 16	E7 protein binds to p48 and blocks IFN- $\alpha/\beta$ signalling
Murine polyoma virus	T antigen binds to and inactivates Jak1
Simian virus 5 (and mumps virus?)	V protein blocks IFN- $\alpha/\beta$ and IFN- $\gamma$ signalling by targetting STAT1 for proteasome-mediated degradation
<b>iii. Miscellaneous</b>	
Hepatitis B virus	Capsid protein specifically inhibits MxA gene expression, mechanism unknown
Human herpesvirus-8	Virus IRF homologue blocks transcriptional responses to IFN- $\alpha/\beta$ and IFN- $\gamma$

STAT1 or STAT2 was specifically degraded. These viruses seem to prevent appropriate phosphorylation of STAT1 (Young *et al.*, 2000; Komatsu *et al.*, 2000). Interestingly, whereas SV5 utilizes the V protein to block IFN signalling, Sendai virus has been shown to use the C protein (Garcin *et al.*, 1999; Gotoh *et al.*, 1999; Komatsu *et al.*, 2000). In contrast, respiratory syncytial virus (another paramyxovirus) does not inhibit IFN signalling, although it clearly has some uncharacterized mechanism for circumventing the IFN response (Young *et al.*, 2000). The adenovirus E1A protein can disrupt transcriptional responses to IFN- $\alpha/\beta$  and IFN- $\gamma$  by decreasing the levels of STAT1 and p48 (Leonard & Sen, 1996), by sequestering the transcriptional co-activator CBP/p300, which binds STAT1 and STAT2 and is involved in transcription responses mediated by these proteins (Bhattacharya *et al.*, 1996; Zhang *et al.*, 1996), and by interacting directly with STAT1 (Look *et al.*, 1998). Furthermore, the multifunctional E7 protein of HPV-16 interacts directly with p48, preventing the formation of ISGF3 and thus the activation of IFN- $\alpha/\beta$ -inducible genes (Barnard & McMillan, 1999).

HHV-8 encodes a homologue of the IRF family that represses transcriptional responses to IFN- $\alpha/\beta$  and IFN- $\gamma$ ; in this case, the inhibition does not appear to act at the level of IFN signalling, but rather inhibits the function of the IFN-inducible product IRF-1 (Zimring *et al.*, 1998), thus transcriptional responses to IFN cannot be sustained. It has been reported that EBNA2 of EBV, which acts as a virus and cellular

transcription factor, also inhibits IFN- $\alpha/\beta$  signalling, by an unknown mechanism that does not prevent the formation of ISGF3 complexes (Kanda *et al.*, 1992). Ebola virus (Harcourt *et al.*, 1998) and hepatitis C virus (HCV) (Heim *et al.*, 1999) also block transcriptional responses to IFN- $\alpha/\beta$  and IFN- $\gamma$ , although the cellular target(s) for inhibition and the viral proteins responsible have yet to be identified in these cases. It has also been reported recently that the capsid protein of HBV inhibits IFN-induction of the MxA gene (Rosmurduc *et al.*, 1999).

Although blocking IFN signalling would seem to be of limited value to viruses in cells that had already been exposed to IFN before infection (such cells would have an established antiviral state), there is some evidence that it can still be advantageous to be able to down-regulate IFN responses. For example, although SV5 cannot initially replicate efficiently in cells that have entered an antiviral state, the ability of the virion-associated V protein to induce STAT1 degradation leads to an eventual decay of the antiviral state and subsequent virus replication (Didcock *et al.*, 1999*b*). Viral proteins that require synthesis after infection might also be able eventually to inactivate an established antiviral state and permit replication, although it should be stressed that the delay in replication induced by IFN exposure would buy time for the host to mount an acquired immune response to help to resolve the infection.

Given that the immune response has co-evolved with viruses and that blocking IFN signalling seems an obvious

**Table 2.** Virus inhibition of IFN-induced antiviral enzymes

Virus	Mechanism of action/inhibition
<b>i. PKR</b>	
Adenovirus	Produces VA RNA that binds to but fails to activate PKR
Baculovirus	PK2 binds eIF2 $\alpha$ kinases, including PKR, and blocks their activities
Epstein–Barr virus	Produces EBER RNA that binds to but fails to activate PKR
Hepatitis C virus	NS5A binds to and inhibits PKR; E2 also interacts with PKR and may inhibit its activity
Herpes simplex virus	ICP 34.5 redirects protein phosphatase 1 to dephosphorylate (re-activate) eIF2 $\alpha$ ; U <sub>s</sub> 11 blocks PKR activity
Human immunodeficiency virus	Down-regulates PKR by unknown mechanism; Tat and short Tat-responsive region RNA inhibit PKR
Influenza virus	NS1 binds dsRNA and PKR to inhibit its activity. Influenza virus also induces cellular inhibitor of PKR (p58IPK)
Poliovirus	Induces the degradation of PKR
Poxviruses (many)	Example: vaccinia virus E3L binds dsRNA and PKR; K3L binds PKR
Reovirus	$\sigma$ 3 binds dsRNA and thus inhibits PKR (and 2'–5' oligoadenylate synthetase)
Rotavirus	NSP3 binds dsRNA and thus inhibits PKR (and 2'–5' oligoadenylate synthetase)
<b>ii. 2'–5' Oligoadenylate synthetase/RNase L system</b>	
Various viruses	Produce proteins that sequester dsRNA (above)
Encephalomyocarditis virus	Induces RNase L inhibitor (RLI) that antagonizes 2'5'A binding to RNase L
Herpes simplex virus	2'5'A derivatives are synthesized that behave as 2'5'A antagonists
Human immunodeficiency virus	Induces RNase L inhibitor (RLI) that antagonizes 2'5'A binding to RNase L

strategy, it would be surprising if the immune system had not evolved a mechanism(s) for recognizing and eliminating cells in which IFN signalling has been blocked. Alternatively, the cell itself may have some compensatory strategy for inducing an antiviral response in cells in which the IFN signal-transduction pathway is blocked. Indeed, this may be an important function of IRF-1, which can bind to and activate many of the promoters normally activated by IFN- $\alpha/\beta$  (Pine, 1992; Henderson *et al.*, 1997; Nguyen *et al.*, 1997). IRF-1 levels can be raised by exposure of cells to a number of cytokines whose levels are up-regulated during infection, such as TNF $\alpha$ , IL-1 and IL-6 (Fujita *et al.*, 1989b; Harroch *et al.*, 1994), and these potential alternative pathways to antiviral gene activation may be important survival mechanisms in the face of a blockade of IFN signalling.

## 6. Inhibition of IFN-induced antiviral enzymes

Many viruses encode factors that down-regulate the activity of IFN-induced antiviral enzymes such as PKR and 2'–5' oligoadenylate synthetase; our current knowledge of these factors is summarized in Table 2 and is discussed below.

(i) **PKR.** The importance of PKR in the induction of an antiviral state can be inferred from the wide variety of mechanisms that are employed by viruses to inhibit its activity (reviewed in Gale & Katze, 1998). As discussed above, a number of viruses encode dsRNA-binding proteins that act to minimize NF- $\kappa$ B activation, IFN induction and apoptosis and these proteins would also inhibit PKR. Interestingly, the dsRNA-binding proteins NS1 (Tan & Katze, 1998) and E3L (Sharp *et al.*, 1998) also bind directly to PKR and inhibit its function, and this is also presumably true of the OV20.0L gene product of orf virus, which shares 33% homology with E3L (Haig *et al.*, 1998). Although the NS1 protein of influenza virus is critical for its ability to overcome the IFN response (Garcia-Sastre *et al.*, 1998; Hatada *et al.*, 1999), influenza virus has also been reported to induce the activation of a cellular inhibitor of PKR termed p58IPK (Lee *et al.*, 1990, 1992, 1994; Melville *et al.*, 1997). NS1 probably also inhibits the IFN response indirectly (as discussed above) by being involved in the virus-induced shut-off of host-cell protein synthesis. Thus, NS1 regulates nuclear export of cellular mRNA (Fortes *et al.*, 1994; Qiu & Krug, 1994) and affects pre-mRNA maturation by inhibiting splicing (Fortes *et al.*, 1994; Lu *et al.*, 1994) and poly-



adenylation-site cleavage (Chen *et al.*, 1999; Shimizu *et al.*, 1999).

In addition to binding dsRNA, viral gene products can inhibit PKR in other ways. Poliovirus induces the degradation of PKR (Black *et al.*, 1989, 1993), HCV encodes the non-structural protein NS5A, which binds PKR directly, thus blocking its activity (Gale *et al.*, 1997), whilst the baculovirus PK2 protein also binds PKR and inhibits its activity (Dever *et al.*, 1998). Furthermore, the E2 protein of HCV contains sequences identical to the phosphorylation sites on PKR and eIF2 $\alpha$  and its interaction with PKR may also contribute to the ability of HCV to circumvent the IFN response (Taylor *et al.*, 1999). The K3L gene product of vaccinia virus has structural similarity to the N terminus of eIF2 $\alpha$  and binds tightly to PKR, preventing autophosphorylation and hence activation of PKR and the subsequent phosphorylation of eIF2 $\alpha$  (Davies *et al.*, 1992, 1993; Carroll *et al.*, 1993).

A more indirect method of overcoming the action of PKR is illustrated by the  $\gamma_1$  ICP34.5 protein encoded by herpes simplex virus (HSV). ICP34.5 interacts with cellular protein phosphatase 1 $\alpha$  (PP1), redirecting it to dephosphorylate, and hence reactivate, eIF2 $\alpha$  (He *et al.*, 1997). A virus deleted in ICP34.5 is attenuated in normal mice but exhibits wild-type replication and virulence in PKR null mice, thereby demonstrating formally the importance of blocking the effects of PKR for HSV pathogenicity (Leib *et al.*, 2000). The I14L protein of ASFV is a homologue of HSV ICP34.5 that contains the sequence thought to be important in its binding to PP1. However, I14L is found predominantly in the nuclei of infected cells and it is not yet clear whether it has a role in circumventing PKR activity (Goatley *et al.*, 1999). Interestingly, HSV also encodes U<sub>S</sub>11 (a  $\gamma_2$  protein), which, when expressed in mutants from an early promoter, can compensate for mutations in ICP34.5 by inhibiting PKR activity. Since U<sub>S</sub>11 is an abundant tegument protein brought into the cells upon infection, it may act early to block phosphorylation of eIF2 $\alpha$ . However, it appears not to be as important as ICP34.5 in preventing PKR-induced switch-off of HSV protein synthesis, and the exact role of U<sub>S</sub>11 in the life-cycle of HSV has yet to be resolved (Mohr & Gluzman, 1996; Cassady *et al.*, 1998).

Some viruses produce abundant short RNA molecules that inhibit PKR (reviewed in Robertson & Mathews, 1996). The adenovirus VAI transcript is an RNA molecule that can form a highly ordered secondary structure that binds avidly to the dsRNA-binding site on PKR and acts as a competitive inhibitor; the molecule is thought to be too short (160 nucleotides) to permit two molecules of PKR to juxtapose and transactivate (reviewed in Mathews, 1993, 1995). EBV also encodes two small RNAs, EBER-1 and EBER-2, that may be analogous to the VA RNAs of adenovirus. Thus, EBER-1 and possibly also EBER-2 can interfere with PKR activity (Sharp *et al.*, 1993). Furthermore, EBER RNAs can partially complement VA-negative mutants of adenovirus (Bhat & Thimmappaya, 1985). Human immunodeficiency virus type 1 (HIV-1) also

produces a short Tat-responsive region (HIV-TAR) RNA that inhibits PKR activity (Gunnery *et al.*, 1990). However, HIV-1 also down-regulates PKR activity by an unknown mechanism (Roy *et al.*, 1990) and the Tat protein, as well as being an activator of virus transcription, also interacts with and inhibits PKR (McMillan *et al.*, 1995; Brand *et al.*, 1997) by both RNA-dependent and RNA-independent mechanisms (Cai *et al.*, 2000).

(ii) **The 2'-5' oligoadenylate synthetase/RNase L system.** Since dsRNA is required to activate 2'-5' oligoadenylate synthetase, virus proteins that sequester dsRNA, e.g. the E3L gene product of vaccinia virus (Rivas *et al.*, 1998), inhibit both PKR and the 2'-5' oligoadenylate synthetase/RNase L system. Several viruses also appear to have evolved strategies that specifically counteract the antiviral activity of the latter pathway. For example, during HSV type 1 and type 2 infection, 2'5'A derivatives are synthesized that behave as 2'5'A antagonists, thereby inhibiting the activation of RNase L (Cayley *et al.*, 1984). Viruses such as HIV-1 (Martinand *et al.*, 1999) and encephalomyocarditis virus (Cayley *et al.*, 1982; Martinand *et al.*, 1998) down-regulate RNase L activity by inducing the expression of the RNase L inhibitor (RLI), which antagonises 2'5'A binding to RNase L and hence prevents its activation.

Surprisingly, a number of the small RNAs produced by viruses that inhibit PKR, including HIV-TAR, adenovirus VAI and EBV EBER-1, appear to activate 2'-5' oligoadenylate synthetase (Desai *et al.*, 1995; Mordechai *et al.*, 1995; Sharp *et al.*, 1999), although the biological reasons for this are unclear.

## Conclusion

The study of how viruses interact with the IFN system has told us much about virus pathogenesis and about the IFN system itself. Future studies on the molecular mechanisms that viruses have for circumventing the IFN response are likely to produce new and unsuspected insights into virus-host relationships. For example, given that viruses have co-evolved with the IFN system, it is possible that viruses have evolved subtle ways of exploiting the IFN response. In this context, it is intriguing to note that the IFN- $\alpha/\beta$ -inducible transcription factor IRF-7 may play a role in altering the pattern of latency in EBV infections (Zhang & Pagano, 2000), whilst HHV-8 can be induced from latency by IFN- $\gamma$  (Chang *et al.*, 2000).

The ability of viruses to block the IFN response may have consequences in terms of the chronic diseases caused by viruses and their treatments. Thus, IFN may be unsuccessful in the treatment of chronic virus infections because the viruses have mechanisms for circumventing the IFN response. For example, it has been suggested that IFN is ineffective as a treatment of some hepatitis C patients because the virus blocks PKR activity (Gale & Katze, 1998).

By understanding the molecular mechanisms by which viruses circumvent the IFN response, it may be possible to

identify novel antiviral drugs that work by preventing viruses from blocking specific cellular activities. Such drugs may be particularly useful in treating chronic virus-induced diseases such as persistent hepatitis B and C infections. In addition, it may be possible to generate attenuated vaccines by altering specifically the virus gene(s) that is responsible for virus inhibition of IFN function. We anticipate that research in the area of IFN–virus interactions will yield a wealth of information that has direct application to the control of virus infections.

We thank Peter King and Paula Barnard for stimulating discussions and The Wellcome Trust for their support.

## References

- Abraham, N., Stojdl, D. F., Duncan, P. I., Methot, N., Ishii, T., Dube, M., Vanderhyden, B. C., Atkins, H. L., Gray, D. A., McBurney, M. W., Koromilas, A. E., Brown, E. G., Sonenberg, N. & Bell, J. C. (1999). Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR. *Journal of Biological Chemistry* **274**, 5953–5962.
- Adams, D. O. & Hamilton, T. A. (1984). The cell biology of macrophage activation. *Annual Review of Immunology* **2**, 283–318.
- Alcami, A. & Smith, G. L. (1995). Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. *Journal of Virology* **69**, 4633–4639.
- Arena, A., Liberto, M. C., Iannello, D., Capozza, A. B. & Foca, A. (1999). Altered cytokine production after human herpes virus type 6 infection. *New Microbiologica* **22**, 293–300.
- Arnheiter, H., Frese, M., Kamadur, R., Meier, E. & Haller, O. (1995). Mx transgenic mice – animal models of health. *Current Topics in Microbiology and Immunology* **206**, 119–147.
- Au, W. C., Moore, P. A., LaFleur, D. W., Tombal, B. & Pitha, P. M. (1998). Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes. *Journal of Biological Chemistry* **273**, 29210–29217.
- Aune, T. M., Penix, L. A., Rincon, M. R. & Flavell, R. A. (1997). Differential transcription directed by discrete gamma interferon promoter elements in naive and memory (effector) CD4 T cells and CD8 T cells. *Molecular and Cellular Biology* **17**, 199–208.
- Bach, E. A., Tanner, J. W., Marsters, S., Ashkenazi, A., Aguet, M., Shaw, A. S. & Schreiber, R. D. (1996). Ligand-induced assembly and activation of the gamma interferon receptor in intact cells. *Molecular and Cellular Biology* **16**, 3214–3221.
- Bach, E. A., Aguet, M. & Schreiber, R. D. (1997). The IFN gamma receptor: a paradigm for cytokine receptor signaling. *Annual Review of Immunology* **15**, 563–591.
- Balachandran, S., Kim, C. N., Yeh, W. C., Mak, T. W., Bhalla, K. & Barber, G. N. (1998). Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. *EMBO Journal* **17**, 6888–6902.
- Balachandran, S., Roberts, P. C., Kipperman, T., Bhalla, K. N., Compans, R. W., Archer, D. R. & Barber, G. N. (2000). Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/caspase-8 death signaling pathway. *Journal of Virology* **74**, 1513–1523.
- Baldwin, A. S., Jr (1996). The NF-kappa B and I kappa B proteins: new discoveries and insights. *Annual Review of Immunology* **14**, 649–683.
- Barnard, P. & McMillan, N. A. (1999). The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon- $\alpha$ . *Virology* **259**, 305–313.
- Bass, B. L., Weintraub, H., Cattaneo, R. & Billeter, M. A. (1989). Biased hypermutation of viral RNA genomes could be due to unwinding/modification of double-stranded RNA. *Cell* **56**, 331–335.
- Bejarano, M. T. & Masucci, M. G. (1998). Interleukin-10 abrogates the inhibition of Epstein–Barr virus-induced B-cell transformation by memory T-cell responses. *Blood* **92**, 4256–4262.
- Bergeron, J., Mabrouk, T., Garzon, S. & Lemay, G. (1998). Characterization of the thermosensitive ts453 reovirus mutant: increased dsRNA binding of sigma 3 protein correlates with interferon resistance. *Virology* **246**, 199–210.
- Bhat, R. A. & Thimmappaya, B. (1985). Construction and analysis of additional adenovirus substitution mutants confirm the complementation of VAI RNA function by two small RNAs encoded by Epstein–Barr virus. *Journal of Virology* **56**, 750–756.
- Bhattacharya, S., Eckner, R., Grossman, S., Oldread, E., Arany, Z., D'Andrea, A. & Livingston, D. M. (1996). Cooperation of Stat2 and p300/CBP in signalling induced by interferon- $\alpha$ . *Nature* **383**, 344–347.
- Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P. & Salazar-Mather, T. P. (1999). Natural killer cells in antiviral defense: function and regulation by innate cytokines. *Annual Review of Immunology* **17**, 189–220.
- Black, T. L., Safer, B., Hovanessian, A. & Katze, M. G. (1989). The cellular 68,000- $M_r$  protein kinase is highly autophosphorylated and activated yet significantly degraded during poliovirus infection: implications for translational regulation. *Journal of Virology* **63**, 2244–2251.
- Black, T. L., Barber, G. N. & Katze, M. G. (1993). Degradation of the interferon-induced 68,000- $M_r$  protein kinase by poliovirus requires RNA. *Journal of Virology* **67**, 791–800.
- Boehm, U., Klamp, T., Groot, M. & Howard, J. C. (1997). Cellular responses to interferon-gamma. *Annual Review of Immunology* **15**, 749–795.
- Bovolenta, C., Lorini, A. L., Mantelli, B., Camorali, L., Novelli, F., Biswas, P. & Poli, G. (1999). A selective defect of IFN-gamma- but not of IFN-alpha-induced JAK/STAT pathway in a subset of U937 clones prevents the antiretroviral effect of IFN-gamma against HIV-1. *Journal of Immunology* **162**, 323–330.
- Brand, S. R., Kobayashi, R. & Mathews, M. B. (1997). The Tat protein of human immunodeficiency virus type 1 is a substrate and inhibitor of the interferon-induced, virally activated protein kinase, PKR. *Journal of Biological Chemistry* **272**, 8388–8395.
- Briscoe, J., Rogers, N. C., Witthuhn, B. A., Watling, D., Harpur, A. G., Wilks, A. F., Stark, G. R., Ihle, J. N. & Kerr, I. M. (1996). Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state. *EMBO Journal* **15**, 799–809.
- Buchmeier, N. A. & Schreiber, R. D. (1985). Requirement of endogenous interferon-gamma production for resolution of *Listeria monocytogenes* infection. *Proceedings of the National Academy of Sciences, USA* **82**, 7404–7408.
- Buschle, M., Campana, D., Carding, S. R., Richard, C., Hoffbrand, A. V. & Brenner, M. K. (1993). Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. *Journal of Experimental Medicine* **177**, 213–218.
- Cai, R., Carpick, B., Chun, R. F., Jeang, K. T. & Williams, B. R. (2000). HIV-1 TAT inhibits PKR activity by both RNA-dependent and RNA-independent mechanisms. *Archives of Biochemistry and Biophysics* **373**, 361–367.

- Cantin, E., Tanamachi, B., Openshaw, H., Mann, J. & Clarke, K. (1999).** Gamma interferon (type II IFN) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than type II IFN ligand null-mutant mice. *Journal of Virology* **73**, 5196–5200.
- Carroll, K., Elroy-Stein, O., Moss, B. & Jagus, R. (1993).** Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent initiation factor 2 alpha-specific protein kinase. *Journal of Biological Chemistry* **268**, 12837–12842.
- Casey, J. L. & Gerin, J. L. (1995).** Hepatitis D virus RNA editing: specific modification of adenosine in the antigenomic RNA. *Journal of Virology* **69**, 7593–7600.
- Cassady, K. A., Gross, M. & Roizman, B. (1998).** The second-site mutation in the herpes simplex virus recombinants lacking the  $\gamma$ 134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2 $\alpha$ . *Journal of Virology* **72**, 7005–7011.
- Castelli, J. C., Hassel, B. A., Maran, A., Paranjape, J., Hewitt, J. A., Li, X. L., Hsu, Y. T., Silverman, R. H. & Youle, R. J. (1998a).** The role of 2'-5' oligoadenylate-activated ribonuclease L in apoptosis. *Cell Death and Differentiation* **5**, 313–320.
- Castelli, J., Wood, K. A. & Youle, R. J. (1998b).** The 2-5A system in viral infection and apoptosis. *Biomedicine & Pharmacotherapy* **52**, 386–390.
- Cattaneo, R. (1994).** Biased (A  $\rightarrow$  I) hypermutation of animal RNA virus genomes. *Current Opinion in Genetics & Development* **4**, 895–900.
- Cayley, P. J., Knight, M. & Kerr, I. M. (1982).** Virus-mediated inhibition of the ppp(A2'p)nA system and its prevention by interferon. *Biochemical and Biophysical Research Communications* **104**, 376–382.
- Cayley, P. J., Davies, J. A., McCullagh, K. G. & Kerr, I. M. (1984).** Activation of the ppp(A2'p)nA system in interferon-treated, herpes simplex virus-infected cells and evidence for novel inhibitors of the ppp(A2'p)nA-dependent RNase. *European Journal of Biochemistry* **15**, 165–174.
- Chang, H. W., Watson, J. L. & Jacobs, B. L. (1992).** The E3L gene of vaccinia virus encodes an inhibitor of PKR. *Proceedings of the National Academy of Sciences, USA* **89**, 4825–4829.
- Chang, J., Renne, R., Dittmer, D. & Ganem, D. (2000).** Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. *Virology* **266**, 17–25.
- Chatterjee-Kishore, M., Kishore, R., Hicklin, D. J., Marincola, F. M. & Ferrone, S. (1998).** Different requirements for signal transducer and activator of transcription 1 $\alpha$  and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. *Journal of Biological Chemistry* **273**, 16177–16183.
- Chebath, J., Benech, P., Revel, M. & Vigneron, M. (1987).** Constitutive expression of (2'-5') oligo A synthetase confers resistance to picornavirus infection. *Nature* **330**, 587–588.
- Chen, Z., Li, Y. & Krug, R. M. (1999).** Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3'-end processing machinery. *EMBO Journal* **18**, 2273–2283.
- Chin, Y. E., Kitagawa, M., Su, W. C., You, Z. H., Iwamoto, Y. & Fu, X. Y. (1996).** Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. *Science* **272**, 719–722.
- Chin, Y. E., Kitagawa, M., Kuida, K., Flavell, R. A. & Fu, X.-Y. (1997).** Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. *Molecular and Cellular Biology* **17**, 5328–5337.
- Chinsangaram, J., Piccone, M. E. & Grubman, M. J. (1999).** Ability of foot-and-mouth disease virus to form plaques in cell culture is associated with suppression of alpha/beta interferon. *Journal of Virology* **73**, 9891–9898.
- Chong, K. L., Feng, L., Schappert, K., Meurs, E., Donahue, T. F., Friesen, J. D., Hovanessian, A. G. & Williams, B. R. (1992).** Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2. *EMBO Journal* **11**, 1553–1562.
- Choubey, D. & Gutterman, J. U. (1997).** Inhibition of E2F-4/DP-1-stimulated transcription by p202. *Oncogene* **15**, 291–301.
- Choubey, D. & Lengyel, P. (1995).** Binding of an interferon-inducible protein (p202) to the retinoblastoma protein. *Journal of Biological Chemistry* **270**, 6134–6140.
- Choubey, D., Li, S. J., Datta, B., Gutterman, J. U. & Lengyel, P. (1996).** Inhibition of E2F-mediated transcription by p202. *EMBO Journal* **15**, 5668–5678.
- Chu, W. M., Ostertag, D., Li, Z. W., Chang, L., Chen, Y., Hu, Y., Williams, B., Perrault, J. & Karin, M. (1999).** JNK2 and IKK $\beta$  are required for activating the innate response to viral infection. *Immunity* **11**, 721–731.
- Clemens, M. J. & Elia, A. (1997).** The double-stranded RNA-dependent protein kinase PKR: structure and function. *Journal of Interferon and Cytokine Research* **17**, 503–524.
- Coccia, E. M., Romeo, G., Nissim, A., Marziali, G., Albertini, R., Affabris, E., Battistini, A., Fiorucci, G., Orsatti, R., Rossi, G. B. and others (1990).** A full-length murine 2-5A synthetase cDNA transfected in NIH-3T3 cells impairs EMCV but not VSV replication. *Virology* **179**, 228–233.
- Colamonici, O., Yan, H., Domanski, P., Handa, R., Smalley, D., Mullersman, J., Witte, M., Krishnan, K. & Krolewski, J. (1994).** Direct binding and tyrosine phosphorylation of the  $\alpha$ -subunit of the type I IFN receptor by the p135<sup>tyk2</sup> tyrosine kinase. *Molecular and Cellular Biology* **14**, 8133–8142.
- Colamonici, O. R., Domanski, P., Sweitzer, S. M., Larner, A. & Buller, R. M. L. (1995).** Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon  $\alpha$  transmembrane signaling. *Journal of Biological Chemistry* **270**, 15974–15978.
- Cousens, L. P., Peterson, R., Hsu, S., Dorner, A., Altman, J. D., Ahmed, R. & Biron, C. A. (1999).** Two roads diverged: interferon alpha/beta- and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection. *Journal of Experimental Medicine* **189**, 1315–1328.
- Cuddihy, A. R., Li, S., Tam, N. W., Wong, A. H., Taya, Y., Abraham, N., Bell, J. C. & Koromilas, A. E. (1999a).** Double-stranded-RNA-activated protein kinase PKR enhances transcriptional activation by tumor suppressor p53. *Molecular and Cellular Biology* **19**, 2475–2484.
- Cuddihy, A. R., Wong, A. H., Tam, N. W., Li, S. & Koromilas, A. E. (1999b).** The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. *Oncogene* **18**, 2690–2702.
- Cuff, S. & Ruby, J. (1996).** Evasion of apoptosis by DNA viruses. *Immunology and Cell Biology* **74**, 527–537.
- Dalton, D. K., Pitts-Meek, S., Keshav, S., Figari, I. S., Bradley, A. & Stewart, T. A. (1993).** Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. *Science* **259**, 1739–1742.
- David, M., Chen, E., Goelz, S., Larner, A. C. & Neel, A. C. (1995).** Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2-domain-containing tyrosine phosphatase SHPTP1. *Molecular and Cellular Biology* **15**, 7050–7058.
- David, M., Zhou, G., Pine, R., Dixon, J. E. & Larner, A. C. (1996).** The SH2 domain-containing tyrosine phosphatase PTP1D is required for interferon alpha/beta-induced gene expression. *Journal of Biological Chemistry* **271**, 15862–15865.



- Davies, M. V., Elroy-Stein, O., Jagus, R., Moss, B. & Kaufman, R. J. (1992). The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2. *Journal of Virology* **66**, 1943–1950.
- Davies, M. V., Chang, H.-W., Jacobs, B. L. & Kaufman, R. J. (1993). The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. *Journal of Virology* **67**, 1688–1692.
- Der, S. D., Yang, Y.-L., Weissmann, C. & Williams, B. R. G. (1997). A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. *Proceedings of the National Academy of Sciences, USA* **94**, 3279–3283.
- Der, S. D., Zhou, A., Williams, B. R. & Silverman, R. H. (1998). Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. *Proceedings of the National Academy of Sciences, USA* **95**, 15623–15628.
- Desai, S. Y., Patel, R. C., Sen, G. C., Malhotra, P., Ghadge, G. D. & Thimmapaya, B. (1995). Activation of interferon-inducible 2′–5′ oligoadenylate synthetase by adenoviral VAI RNA. *Journal of Biological Chemistry* **270**, 3454–3461.
- Dever, T. E., Chen, J. J., Barber, J. N., Cigan, A. M., Feng, L., Donahue, T. F., London, I. M., Katze, M. G. & Hinnebusch, A. G. (1993). Mammalian eukaryotic initiation 2 $\alpha$  kinase functionally substitutes for GCN 2 protein kinase in the GCN 4 translational control mechanism of yeast. *Proceedings of the National Academy of Sciences, USA* **90**, 4616–4620.
- Dever, T. E., Sripriya, R., McLachlin, J. R., Lu, J., Fabian-Matcher, J. R., Kimball, S. R. & Miller, L. K. (1998). Disruption of cellular translational control by a viral truncated eukaryotic translation initiation factor 2 $\alpha$  kinase homolog. *Proceedings of the National Academy of Sciences, USA* **95**, 4164–4169.
- Diaz-Guerra, M., Rivas, C. & Esteban, M. (1997). Activation of the IFN-inducible enzyme RNase L causes apoptosis of animal cells. *Virology* **236**, 354–363.
- Didcock, L., Young, D. F., Goodbourn, S. & Randall, R. E. (1999a). Sendai virus and simian virus 5 block activation of interferon-responsive genes. *Journal of Virology* **73**, 3125–3133.
- Didcock, L., Young, D. F., Goodbourn, S. & Randall, R. E. (1999b). The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. *Journal of Virology* **73**, 9928–9933.
- Dighe, A. S., Campbell, D., Hsieh, C. S., Clarke, S., Greaves, D. R., Gordon, S., Murphy, K. M. & Schreiber, R. D. (1995). Tissue-specific targeting of cytokine unresponsiveness in transgenic mice. *Immunity* **3**, 657–666.
- Doherty, T. M., Seder, R. A. & Sher, A. (1996). Induction and regulation of IL-15 expression in murine macrophages. *Journal of Immunology* **156**, 735–741.
- Dorman, S. E., Uzel, G., Roesler, J., Bradley, J. S., Bastian, J., Billman, G., King, S., Filie, A., Schermerhorn, J. & Holland, S. M. (1999). Viral infections in interferon-gamma receptor deficiency. *Journal of Pediatrics* **135**, 640–643.
- Du, W., Thanos, D. & Maniatis, T. (1993). Mechanism of transcriptional synergism between distinct virus-inducible enhancer elements. *Cell* **74**, 887–898.
- Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, A., Tanimura, S., Ohtsubo, M., Misawa, H., Miyazaki, T., Leonor, N., Taniguchi, T., Fujita, T., Kanakura, Y., Komiya, S. & Yoshimura, A. (1997). A new protein containing an SH2 domain that inhibits JAK kinases. *Nature* **387**, 921–924.
- Epperson, D. E., Arnold, D., Spies, T., Cresswell, P., Pober, J. S. & Johnson, D. R. (1992). Cytokines increase transporter in antigen processing-1 expression more rapidly than HLA class I expression in endothelial cells. *Journal of Immunology* **149**, 3297–3301.
- Erlandsson, L., Blumenthal, R., Eloranta, M. L., Engel, H., Alm, G., Weiss, S. & Leanderson, T. (1998). Interferon-beta is required for interferon-alpha production in mouse fibroblasts. *Current Biology* **8**, 223–226.
- Fawaz, L. M., Sharif-Askari, E. & Menezes, J. (1999). Up-regulation of NK cytotoxic activity via IL-15 induction by different viruses: a comparative study. *Journal of Immunology* **163**, 4473–4480.
- Fehniger, T. A., Shah, M. H., Turner, M. J., VanDeusen, J. B., Whitman, S. P., Cooper, M. A., Suzuki, K., Wechsler, M., Goodsaid, F. & Caligiuri, M. A. (1999). Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. *Journal of Immunology* **162**, 4511–4520.
- Ferran, M. C. & Lucas-Lenard, J. M. (1997). The vesicular stomatitis virus matrix protein inhibits transcription from the human beta interferon promoter. *Journal of Virology* **71**, 371–377.
- Fiette, L., Aubert, C., Muller, U., Huang, S., Aguet, M., Brahic, M. & Bureau, J. F. (1995). Theiler's virus infection of 129Sv mice that lack the interferon alpha/beta or interferon gamma receptors. *Journal of Experimental Medicine* **181**, 2069–2076.
- Flati, V., Haque, S. J. & Williams, B. R. (1996). Interferon-alpha-induced phosphorylation and activation of cytosolic phospholipase A2 is required for the formation of interferon-stimulated gene factor three. *EMBO Journal* **15**, 1566–1571.
- Flesch, I. E., Hess, J. H., Huang, S., Aguet, M., Rothe, J., Bluethmann, H. & Kaufmann, S. H. (1995). Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. *Journal of Experimental Medicine* **181**, 1615–1621.
- Foo, S. Y. & Nolan, G. P. (1999). NF- $\kappa$ B to the rescue: RELs, apoptosis and cellular transformation. *Trends in Genetics* **15**, 229–235.
- Fortes, P., Beloso, A. & Ortin, J. (1994). Influenza virus NS1 protein inhibits pre-mRNA splicing and blocks mRNA nucleocytoplasmic transport. *EMBO Journal* **13**, 704–712.
- Foss, G. S. & Prydz, H. (1999). Interferon regulatory factor 1 mediates the interferon-gamma induction of the human immunoproteasome subunit multicatalytic endopeptidase complex-like 1. *Journal of Biological Chemistry* **274**, 35196–35202.
- Frese, M., Kochs, G., Meier-Dieter, U., Siebler, J. & Haller, O. (1995). Human MxA protein inhibits tick-borne Thogoto virus but not Dhori virus. *Journal of Virology* **69**, 3904–3909.
- Frese, M., Kochs, G., Feldmann, H., Hertkorn, C. & Haller, O. (1996). Inhibition of bunyaviruses, phleboviruses and hantaviruses by human MxA protein. *Journal of Virology* **70**, 915–923.
- Frese, M., Weeber, M., Weber, F., Speth, V. & Haller, O. (1997). Mx1 sensitivity: Batken virus is an orthomyxovirus closely related to Dhori virus. *Journal of General Virology* **78**, 2453–2458.
- Friedman, R. L., Manly, S. P., McMahon, M., Kerr, I. M. & Stark, G. R. (1984). Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. *Cell* **38**, 745–755.
- Fujimoto, I., Takizawa, T., Ohba, Y. & Nakanishi, Y. (1998). Co-expression of Fas and Fas-ligand on the surface of influenza virus-infected cells. *Cell Death and Differentiation* **5**, 426–431.
- Fujita, T., Kimura, Y., Miyamoto, M., Barsoumian, E. L. & Taniguchi, T. (1989a). Induction of endogenous IFN- $\alpha$  and IFN- $\beta$  genes by a regulatory transcription factor, IRF-1. *Nature* **337**, 270–272.



- Fujita, T., Reis, L. F., Watanabe, N., Kimura, Y., Taniguchi, T. & Vilcek, J. (1989b).** Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways. *Proceedings of the National Academy of Sciences, USA* **86**, 9936–9940.
- Furukawa, Y., Iwase, S., Kikuchi, J., Nakamura, M., Yamada, H. & Matsuda, M. (1999).** Transcriptional repression of the E2F-1 gene by interferon-alpha is mediated through induction of E2F-4/pRB and E2F-4/p130 complexes. *Oncogene* **18**, 2003–2014.
- Gajewski, T. F. & Fitch, F. W. (1988).** Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. *Journal of Immunology* **140**, 4245–4252.
- Gale, M., Jr & Katze, M. G. (1998).** Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. *Pharmacology & Therapeutics* **78**, 29–46.
- Gale, M. J., Jr, Korth, M. J., Tang, N. M., Tan, S.-L., Hopkins, D. A., Dever, T. E., Polyak, S. J., Gretch, D. R. & Katze, M. G. (1997).** Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. *Virology* **230**, 217–227.
- Garcia-Sastre, A., Durbin, R. K., Zheng, H., Palese, P., Gertner, R., Levy, D. E. & Durbin, J. E. (1998).** The role of interferon in influenza virus tissue tropism. *Journal of Virology* **72**, 8550–8558.
- Garcin, D., Latorre, P. & Kolakofsky, D. (1999).** Sendai virus C proteins counteract the interferon-mediated induction of an antiviral state. *Journal of Virology* **73**, 6559–6565.
- Gartel, A. L., Serfas, M. S. & Tyner, A. L. (1996).** p21 – negative regulator of the cell cycle. *Proceedings of the Society for Experimental Biology and Medicine* **213**, 138–149.
- George, C. X., Thomis, D. C., McCormack, S. J., Svahn, C. M. & Samuel, C. E. (1996).** Characterization of the heparin-mediated activation of PKR, the interferon-inducible RNA-dependent protein kinase. *Virology* **221**, 180–188.
- Gil, J., Alcami, J. & Esteban, M. (1999).** Induction of apoptosis by double-stranded-RNA-dependent protein kinase (PKR) involves the alpha subunit of eukaryotic translation initiation factor 2 and NF-kappaB. *Molecular and Cellular Biology* **19**, 4653–4663.
- Gillet, G. & Brun, G. (1996).** Viral inhibition of apoptosis. *Trends in Microbiology* **4**, 312–317.
- Goatley, L. C., Marron, M. B., Jacobs, S. C., Hammond, J. M., Miskin, J. E., Abrams, C. C., Smith, G. L. & Dixon, L. K. (1999).** Nuclear and nucleolar localization of an African swine fever virus protein, I14L, that is similar to the herpes simplex virus-encoded virulence factor ICP34.5. *Journal of General Virology* **80**, 525–535.
- Goh, K. C., Haque, S. J. & Williams, B. R. (1999).** p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. *EMBO Journal* **18**, 5601–5608.
- Gosselin, J., Tomolu, A., Gallo, R. C. & Flamand, L. (1999).** Interleukin-15 as an activator of natural killer cell-mediated antiviral response. *Blood* **94**, 4210–4219.
- Gotoh, B., Takeuchi, K., Komatsu, T., Yokoo, J., Kimura, Y., Kurotani, A., Kato, A. & Nagai, Y. (1999).** Knockout of the Sendai virus C gene eliminates the viral ability to prevent the interferon-alpha/beta-mediated responses. *FEBS Letters* **459**, 205–210.
- Grawunder, U., Melchers, F. & Rolink, A. (1993).** Interferon-gamma arrests proliferation and causes apoptosis in stromal cell/interleukin-7-dependent normal murine pre-B cell lines and clones in vitro, but does not induce differentiation to surface immunoglobulin-positive B cells. *European Journal of Immunology* **23**, 544–551.
- Greenlund, A. C., Farrar, M. A., Viviano, B. L. & Schreiber, R. D. (1994).** Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). *EMBO Journal* **13**, 1591–1600.
- Greenlund, A. C., Morales, M. O., Viviano, B. L., Yan, H., Krolewski, J. & Schreiber, R. D. (1995).** Stat recruitment by tyrosine-phosphorylated cytokine receptors: an ordered reversible affinity-driven process. *Immunity* **2**, 677–687.
- Grieder, F. B. & Vogel, S. N. (1999).** Role of interferon and interferon regulatory factors in early protection against Venezuelan equine encephalitis virus infection. *Virology* **257**, 106–118.
- Grob, P., Schijns, V. E., van den Broek, M. F., Cox, S. P., Ackermann, M. & Suter, M. (1999).** Role of the individual interferon systems and specific immunity in mice in controlling systemic dissemination of attenuated pseudorabies virus infection. *Journal of Virology* **73**, 4748–4754.
- Gunnery, S., Rice, A. P., Robertson, H. D. & Mathews, M. B. (1990).** Tat-responsive region RNA of human immunodeficiency virus 1 can prevent activation of the double-stranded-RNA-activated protein kinase. *Proceedings of the National Academy of Sciences, USA* **87**, 8687–8691.
- Gutterman, J. U. & Choubey, D. (1999).** Retardation of cell proliferation after expression of p202 accompanies an increase in p21(WAF1/CIP1). *Cell Growth & Differentiation* **10**, 93–100.
- Haig, D. M., McInnes, C. J., Thomson, J., Wood, A., Bunyan, K. & Mercer, A. (1998).** The orf virus OV20.0L gene product is involved in interferon resistance and inhibits an interferon-inducible, double-stranded RNA-dependent kinase. *Immunology* **93**, 335–340.
- Hajjar, A. M. & Linial, M. L. (1995).** Modification of retroviral RNA by double-stranded RNA adenosine deaminase. *Journal of Virology* **69**, 5878–5882.
- Haller, O., Frese, M., Rost, D., Nuttall, P. A. & Kochs, G. (1995).** Tick-borne Thogoto virus infection in mice is inhibited by the orthomyxovirus resistance gene product Mx1. *Journal of Virology* **69**, 2596–2601.
- Hannigan, G. E. & Williams, B. R. (1991).** Signal transduction by interferon-alpha through arachidonic acid metabolism. *Science* **251**, 204–207.
- Haque, S. J. & Williams, B. R. (1994).** Identification and characterization of an interferon (IFN)-stimulated response element-IFN-stimulated gene factor 3-independent signaling pathway for IFN-alpha. *Journal of Biological Chemistry* **269**, 19523–19529.
- Haque, S. J. & Williams, B. R. (1998).** Signal transduction in the interferon system. *Seminars in Oncology* **25**, 14–22.
- Haque, S. J., Flati, V., Deb, A. & Williams, B. R. (1995).** Roles of protein-tyrosine phosphatases in Stat1 alpha-mediated cell signaling. *Journal of Biological Chemistry* **270**, 25709–25714.
- Harada, H., Fujita, T., Miyamoto, M., Kimura, Y., Maruyama, M., Furia, A., Miyata, T. & Taniguchi, T. (1989).** Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. *Cell* **58**, 729–739.
- Harcourt, B. H., Sanchez, A. & Offermann, M. K. (1998).** Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells. *Virology* **252**, 179–188.
- Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. & Elledge, S. J. (1993).** The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. *Cell* **75**, 805–816.
- Harroch, S., Revel, M. & Chebath, J. (1994).** Induction by interleukin-6 of interferon regulatory factor 1 (IRF-1) gene expression through the palindromic interferon response element pIRE and cell type-dependent control of IRF-1 binding to DNA. *EMBO Journal* **13**, 1942–1949.
- Hassel, B. A., Zhou, A., Sotomayor, C., Maran, A. & Silverman, R. H.**

- (1993). A dominant negative mutant of 2–5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. *EMBO Journal* **12**, 3297–3304.
- Hatada, E., Saito, S. & Fukuda, R. (1999).** Mutant influenza viruses with a defective NS1 protein cannot block the activation of PKR in infected cells. *Virology* **73**, 2425–2433.
- He, B., Gross, M. & Roizman, B. (1997).** The  $\gamma_134.5$  protein of herpes simplex virus 1 complexes with protein phosphatase 1a to dephosphorylate the  $\alpha$  subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. *Proceedings of the National Academy of Sciences, USA* **94**, 843–848.
- Hefti, H. P., Frese, M., Landis, H., Di Paolo, C., Aguzzi, A., Haller, O. & Pavlovic, J. (1999).** Human MxA protein protects mice lacking a functional alpha/beta interferon system against La crosse virus and other lethal viral infections. *Journal of Virology* **73**, 6984–6991.
- Heim, M. H., Kerr, I. M., Stark, G. R. & Darnell, J. E., Jr (1995).** Contribution of STAT SH2 groups to specific interferon signaling by the Jak–STAT pathway. *Science* **267**, 1347–1349.
- Heim, M. H., Moradpur, D. & Blum, H. E. (1999).** Expression of hepatitis C virus proteins inhibits signal transduction through the Jak–STAT pathway. *Journal of Virology* **73**, 8469–8475.
- Henderson, Y. C., Chou, M. & Deisseroth, A. B. (1997).** Interferon regulatory factor 1 induces the expression of the interferon-stimulated genes. *British Journal of Haematology* **96**, 566–575.
- Horikami, S. M. & Moyer, S. A. (1995).** Double-stranded RNA adenosine deaminase activity during measles virus infection. *Virus Research* **36**, 87–96.
- Hsieh, C. S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A. & Murphy, K. M. (1993).** Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. *Science* **260**, 547–549.
- Hsu, D. H., de Waal Malefyt, R., Fiorentino, D. F., Dang, M. N., Vieira, P., de Vries, J., Spits, H., Mosmann, T. R. & Moore, K. W. (1990).** Expression of interleukin-10 activity by Epstein–Barr virus protein BCRF1. *Science* **250**, 830–832.
- Huang, S., Hendriks, W., Althage, A., Hemmi, S., Bluethmann, H., Kamijo, R., Vilcek, J., Zinkernagel, R. M. & Aguet, M. (1993).** Immune response in mice that lack the interferon-gamma receptor. *Science* **259**, 1742–1745.
- Hwang, S. Y., Hertzog, P. J., Holland, K. A., Sumarsono, S. H., Tymms, M. J., Hamilton, J. A., Whitty, G., Bertoncello, I. & Kola, I. (1995).** A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. *Proceedings of the National Academy of Sciences, USA* **92**, 11284–11288.
- Igarashi, K., David, M., Larner, A. C. & Finbloom, D. S. (1993).** In vitro activation of a transcription factor by gamma interferon requires a membrane-associated tyrosine kinase and is mimicked by vanadate. *Molecular and Cellular Biology* **13**, 3984–3989.
- Igarashi, K., Garotta, G., Ozmen, L., Ziemiecki, A., Wilks, A. F., Harpur, A. G., Larner, A. C. & Finbloom, D. S. (1994).** Interferon-gamma induces tyrosine phosphorylation of interferon-gamma receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor. *Journal of Biological Chemistry* **269**, 14333–14336.
- Iordanov, M. S., Paranjape, J. M., Zhou, A., Wong, J., Williams, B. R., Meurs, E. F., Silverman, R. H. & Magun, B. E. (2000).** Activation of p38 mitogen-activated protein kinase and c-Jun NH<sub>2</sub>-terminal kinase by double-stranded RNA and encephalomyocarditis virus: involvement of RNase L, protein kinase R, and alternative pathways. *Molecular and Cellular Biology* **20**, 617–627.
- Israel, A. (2000).** The IKK complex: an integrator of signals that activate NF- $\kappa$ B? *Trends in Cell Biology* **10**, 129–133.
- Iwase, S., Furukawa, Y., Kikuchi, J., Nagai, M., Terui, Y., Nakamura, M. & Yamada, H. (1997).** Modulation of E2F activity is linked to interferon-induced growth suppression of hematopoietic cells. *Journal of Biological Chemistry* **272**, 12406–12414.
- Jacobs, B. L. & Langland, J. O. (1996).** When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. *Virology* **219**, 339–349.
- Jacobs, B. L. & Langland, J. O. (1998).** Reovirus sigma 3 protein: dsRNA binding and inhibition of RNA-activated protein kinase. *Current Topics in Microbiology and Immunology* **233**, 185–196.
- Jagus, R., Joshi, B. & Barber, G. N. (1999).** PKR, apoptosis and cancer. *International Journal of Biochemistry and Cell Biology* **31**, 123–138.
- Janknecht, R. & Hunter, T. (1996).** Transcription. A growing coactivator network. *Nature* **383**, 22–23.
- Jaramillo, M. L., Abraham, N. & Bell, J. C. (1995).** The interferon system: a review with emphasis on the role of PKR in growth control. *Cancer Investigations* **13**, 327–338.
- Johnson, A. J. & Roehrig, J. T. (1999).** New mouse model for dengue virus vaccine testing. *Journal of Virology* **73**, 783–786.
- Johnstone, R. W., Kerry, J. A. & Trapani, J. A. (1998).** The human interferon-inducible protein, IFI 16, is a repressor of transcription. *Journal of Biological Chemistry* **273**, 17172–17177.
- Kanda, K., Decker, T., Aman, P., Wahlstrom, M., von Gabain, A. & Kallin, B. (1992).** The EBNA2-related resistance towards  $\alpha$  interferon (IFN- $\alpha$ ) in Burkitt's lymphoma cells effects induction of IFN-induced genes but not the activation of transcription factor ISGF-3. *Molecular and Cellular Biology* **12**, 4930–4936.
- Kanerva, M., Melen, K., Vaheri, A. & Julkunen, I. (1996).** Inhibition of puumala and tula hantaviruses in Vero cells by MxA protein. *Virology* **224**, 55–62.
- Kano, A., Haruyama, T., Akaike, T. & Watanabe, Y. (1999).** IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. *Biochemical and Biophysical Research Communications* **257**, 672–677.
- Kaplan, D. H., Greenlund, A. C., Tanner, J. W., Shaw, A. S. & Schreiber, R. D. (1996).** Identification of an interferon-gamma receptor alpha chain sequence required for JAK-1 binding. *Journal of Biological Chemistry* **271**, 9–12.
- Karlsen, A. E., Pavlovic, D., Nielsen, K., Jensen, J., Andersen, H. U., Pociot, F., Mandrup-Poulsen, T., Eizirik, D. L. & Nerup, J. (2000).** Interferon-gamma induces interleukin-1 converting enzyme expression in pancreatic islets by an interferon regulatory factor-1-dependent mechanism. *Journal of Clinical Endocrinology & Metabolism* **85**, 830–836.
- Kaser, A., Enrich, B., Ludwiczek, O., Vogel, W. & Tilg, H. (1999).** Interferon- $\alpha$  (IFN- $\alpha$ ) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway. *Clinical and Experimental Immunology* **118**, 71–77.
- Katze, M. G., Wambach, M., Wong, M. L., Garfinkel, M., Meurs, E., Chong, K., Williams, B. R., Hovanessian, A. G. & Barber, G. N. (1991).** Functional expression and RNA binding analysis of the interferon-induced, double-stranded RNA-activated, 68,000- $M_r$  protein kinase in a cell-free system. *Molecular and Cellular Biology* **11**, 5497–5505.
- Kerr, I. M. & Brown, R. E. (1978).** pppA<sub>2</sub>'p5'A<sub>2</sub>'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. *Proceedings of the National Academy of Sciences, USA* **75**, 256–260.

- Kim, T. K. & Maniatis, T. (1996).** Regulation of interferon- $\gamma$ -activated STAT1 by the ubiquitin-proteasome pathway. *Science* **273**, 1717–1719.
- Kimura, T., Nakayama, K., Penninger, J., Kitagawa, M., Harada, H., Matsuyama, T., Tanaka, N., Kamijo, R., Vilcek, J., Mak, T. W. & Taniguchi, T. (1994).** Involvement of the IRF-1 transcription factor in antiviral responses to interferons. *Science* **264**, 1921–1924.
- King, P. & Goodbourn, S. (1998).** STAT1 is inactivated by a caspase. *Journal of Biological Chemistry* **273**, 8699–8704.
- Kingsmore, S. F., Snoddy, J., Choubey, D., Lengyel, P. & Seldin, M. F. (1989).** Physical mapping of a family of interferon-activated genes, serum amyloid P-component, and alpha-spectrin on mouse chromosome 1. *Immunogenetics* **30**, 169–174.
- Kirch, H. C., Putzer, B., Brockmann, D., Esche, H. & Kloke, O. (1997).** Formation of the early-region-2 transcription-factor-1-retinoblastoma-protein (E2F-1-RB) transrepressor and release of the retinoblastoma protein from nuclear complexes containing cyclin A is induced by interferon alpha in U937V cells but not in interferon-alpha-resistant U937VR cells. *European Journal of Biochemistry* **246**, 736–744.
- Komatsu, T., Takeuchi, K., Yokoo, J., Tanaka, Y. & Gotoh, B. (2000).** Sendai virus blocks alpha interferon signaling to signal transducers and activators of transcription. *Journal of Virology* **74**, 2477–2480.
- Koromilas, A. E., Roy, S., Barber, G. N., Katze, M. G. & Sonenberg, N. (1992).** Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. *Science* **257**, 1685–1689.
- Kotenko, S. V., Izotova, L. S., Pollack, B. P., Mariano, T. M., Donnelly, R. J., Muthukumaran, G., Cook, J. R., Garotta, G., Silvennoinen, O., Ihle, J. N. & Kerr, I. (1995).** Interaction between the components of the interferon gamma receptor complex. *Journal of Biological Chemistry* **270**, 20915–20921.
- Kovarik, P., Stoiber, D., Eyers, P. A., Menghini, R., Neininger, A., Gaestel, M., Cohen, P. & Decker, T. (1999).** Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway. *Proceedings of the National Academy of Sciences, USA* **96**, 13956–13961.
- Kumar, A., Haque, J., Lacoste, J., Hiscott, J. & Williams, B. R. G. (1994).** Double-stranded RNA-dependent protein kinase activates transcription factor NF- $\kappa$ B by phosphorylating I $\kappa$ B. *Proceedings of the National Academy of Sciences, USA* **91**, 6288–6292.
- Kumar, A., Yang, Y. L., Flati, V., Der, S., Kadereit, S., Deb, A., Haque, J., Reis, L., Weissmann, C. & Williams, B. R. (1997).** Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF- $\kappa$ B. *EMBO Journal* **16**, 406–416.
- Landis, H., Simon-Jodicke, A., Klotz, A., Di Paolo, C., Schnorr, J. J., Schneider-Schaulies, S., Hefti, H. P. & Pavlovic, J. (1998).** Human MxA protein confers resistance to Semliki Forest virus and inhibits the amplification of a Semliki Forest virus-based replicon in the absence of viral structural proteins. *Journal of Virology* **72**, 1516–1522.
- Langland, J. O., Pettiford, S., Jiang, B. & Jacobs, B. L. (1994).** Products of the porcine group C rotavirus NSP3 gene bind specifically to double-stranded RNA and inhibit activation of the interferon-induced protein kinase PKR. *Journal of Virology* **68**, 3821–3829.
- Larner, A. C., Chaudhuri, A. & Darnell, J. E., Jr (1986).** Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction. *Journal of Biological Chemistry* **261**, 453–459.
- Lechleitner, S., Gille, J., Johnson, D. R. & Petzelbauer, P. (1998).** Interferon enhances tumor necrosis factor-induced vascular cell adhesion molecule 1 (CD106) expression in human endothelial cells by an interferon-related factor 1-dependent pathway. *Journal of Experimental Medicine* **187**, 2023–2030.
- Lee, T. G., Tomita, J., Hovanessian, A. G. & Katze, M. G. (1990).** Purification and partial characterization of a cellular inhibitor of the interferon-induced protein kinase of  $M_r$  68,000 from influenza virus-infected cells. *Proceedings of the National Academy of Sciences, USA* **87**, 6208–6212.
- Lee, T. G., Tomita, J., Hovanessian, A. G. & Katze, M. G. (1992).** Characterization and regulation of the 58,000-dalton cellular inhibitor of the interferon-induced, dsRNA-activated protein kinase. *Journal of Biological Chemistry* **267**, 14238–14243.
- Lee, T. G., Tang, N., Thompson, S., Miller, J. & Katze, M. G. (1994).** The 58,000-dalton cellular inhibitor of the interferon-induced double-stranded RNA-activated protein kinase (PKR) is a member of the tetratricopeptide repeat family of proteins. *Molecular and Cellular Biology* **14**, 2331–2342.
- Lee, S. B., Rodriguez, D., Rodriguez, J. R. & Esteban, M. (1997).** The apoptosis pathway triggered by the interferon-induced protein kinase PKR requires the third basic domain, initiates upstream of Bcl-2, and involves ICE-like proteases. *Virology* **231**, 81–88.
- Leib, D. A., Machalek, M. A., Williams, B. R. G., Silverman, R. H. & Virgin, H. W. (2000).** Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. *Proceedings of the National Academy of Sciences, USA* **97**, 6097–6101.
- Leombo, D., Angeretti, A., Benefazio, S., Hertel, L., Gariglio, M., Novelli, F. & Landolfo, S. (1995).** Constitutive expression of the interferon-inducible protein p202 in NIH 3T3 cells affects cell cycle progression. *Journal of Biological Regulators and Homeostatic Agents* **9**, 42–46.
- Lenardo, M. J., Fan, C.-M., Maniatis, T. & Baltimore, D. (1989).** The involvement of NF- $\kappa$ B in  $\beta$ -interferon gene regulation reveals its role as a widely inducible mediator of signal transduction. *Cell* **57**, 287–294.
- Leonard, G. T. & Sen, G. C. (1996).** Effects of adenovirus E1A protein on interferon-signaling. *Virology* **224**, 25–33.
- Leung, S., Qureshi, S. A., Kerr, I. M., Darnell, J. E., Jr & Stark, G. R. (1995).** Role of STAT2 in the alpha interferon signaling pathway. *Molecular and Cellular Biology* **15**, 1312–1317.
- Li, X., Leung, S., Kerr, I. M. & Stark, G. R. (1997).** Functional subdomains of STAT2 required for preassociation with the alpha interferon receptor and for signaling. *Molecular and Cellular Biology* **17**, 2048–2056.
- Liu, Z. G., Hsu, H., Goeddel, D. V. & Karin, M. (1996).** Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. *Cell* **87**, 565–576.
- Lloyd, R. M. & Shatkin, A. J. (1992).** Translational stimulation by reovirus polypeptide sigma 3: substitution for VAI RNA and inhibition of phosphorylation of the alpha subunit of eukaryotic initiation factor 2. *Journal of Virology* **66**, 6878–6884.
- Look, D. C., Roswit, W. T., Frick, A. G., Gris-Alevy, Y., Dickhaus, D. M., Walter, M. J. & Holtzman, M. J. (1998).** Direct suppression of Stat1 function during adenoviral infection. *Immunity* **9**, 871–880.
- Lu, Y., Qian, X. Y. & Krug, R. M. (1994).** The influenza virus NS1 protein: a novel inhibitor of pre-mRNA splicing. *Genes & Development* **8**, 1817–1828.
- Lu, Y., Wambach, M., Katze, M. G. & Krug, R. M. (1995).** Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the eIF-2 translation initiation factor. *Virology* **214**, 222–228.
- Lu, H. T., Yang, D. D., Wusk, M., Gatti, E., Mellman, I., Davis, R. J. & Flavell, R. A. (1999).** Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. *EMBO Journal* **18**, 1845–1857.



- MacMicking, J., Xie, Q. W. & Nathan, C. (1997). Nitric oxide and macrophage function. *Annual Review of Immunology* **15**, 323–350.
- McMillan, N. A., Chun, R. F., Siderovski, D. P., Galabru, J., Toone, W. M., Samuel, C. E., Mak, T. W., Hovanessian, A. G., Jeang, K. T. & Williams, B. R. (1995). HIV-1 Tat directly interacts with the interferon-induced, double-stranded RNA-dependent kinase, PKR. *Virology* **213**, 413–424.
- Maran, A., Maitra, R. K., Kumar, A., Dong, B., Xiao, W., Li, G., Williams, B. R., Torrence, P. F. & Silverman, R. H. (1994). Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2–5A antisense chimeras. *Science* **265**, 789–792.
- Marie, I., Durbin, J. E. & Levy, D. E. (1998). Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. *EMBO Journal* **17**, 6660–6669.
- Marrack, P., Kappler, J. & Mitchell, T. (1999). Type I interferons keep activated T cells alive. *Journal of Experimental Medicine* **189**, 521–530.
- Martinand, C., Salehzada, T., Silhol, M., Lebleu, B. & Bisbal, C. (1998). RNase L inhibitor (RLI) antisense constructions block partially the down regulation of the 2–5A/RNase L pathway in encephalomyocarditis-virus-(EMCV)-infected cells. *European Journal of Biochemistry* **254**, 248–255.
- Martinand, C., Montavon, C., Salehzada, T., Silhol, M., Lebleu, B. & Bisbal, C. (1999). RNase L inhibitor induced during human immunodeficiency virus type 1 infection and down regulates the 2–5A/RNase L pathway in human T cells. *Journal of Virology* **73**, 290–296.
- Martinez-Costas, J., Gonzalez-Lopez, C., Vakharia, V. N. & Benavente, J. (2000). Possible involvement of the double-stranded RNA-binding core protein  $\sigma A$  in the resistance of avian reovirus to interferon. *Journal of Virology* **74**, 1124–1131.
- Mathews, M. B. (1993). Viral evasion of cellular defense mechanisms: regulation of the protein kinase DAI by RNA effectors. *Seminars in Virology* **4**, 247–257.
- Mathews, M. B. (1995). Structure, function, and evolution of adenovirus virus-associated RNAs. *Current Topics in Microbiology and Immunology* **199**, 173–187.
- Matsuyama, T., Kimura, T., Kitagawa, M., Pfeffer, K., Kawakami, T., Watanabe, N., Kundig, T., Amakawa, R., Kishihara, K., Wakeham, A., Potter, J., Furlonger, C. L., Narendran, A., Suzuki, H., Ohashi, P. S., Paige, C. J., Taniguchi, T. & Mak, T. W. (1993). Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. *Cell* **75**, 83–97.
- Melville, M. W., Hansen, W. J., Freeman, B. C., Welch, W. J. & Katze, M. G. (1997). The molecular chaperone hsp40 regulates the activity of P58IPK, the cellular inhibitor of PKR. *Proceedings of the National Academy of Sciences, USA* **94**, 97–102.
- Meurs, E., Chong, K., Galabru, J., Thomas, N. S., Kerr, I. M., Williams, B. R. & Hovanessian, A. G. (1990). Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. *Cell* **62**, 379–390.
- Meurs, E. F., Watanabe, Y., Kadereit, S., Barber, G. N., Katze, M. G., Chong, K., Williams, B. R. & Hovanessian, A. G. (1992). Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus growth. *Journal of Virology* **66**, 5804–5814.
- Miller, D. M., Rahill, B. M., Boss, J. M., Lairmore, M. D., Durbin, J. E., Waldman, J. W. & Sedmak, D. D. (1998). Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/STAT pathway. *Journal of Experimental Medicine* **187**, 675–683.
- Miller, D. M., Zhang, Y., Rahill, B. M., Waldman, W. J. & Sedmak, D. D. (1999). Human cytomegalovirus inhibits IFN- $\alpha$ -stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN- $\alpha$  signal transduction. *Journal of Immunology* **162**, 6107–6113.
- Miyamoto, M., Fujita, T., Kimura, Y., Maruyama, M., Harada, H., Sudo, Y., Miyata, T. & Taniguchi, T. (1988). Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN- $\beta$  gene regulatory elements. *Cell* **54**, 903–913.
- Mogensen, K. E., Lewerenz, M., Reboul, J., Lutfalla, G. & Uze, G. (1999). The type I interferon receptor: structure, function, and evolution of a family business. *Journal of Interferon & Cytokine Research* **19**, 1069–1098.
- Mohr, I. & Gluzman, Y. (1996). A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. *EMBO Journal* **15**, 4759–4766.
- Mordechai, E., Kon, N., Henderson, E. E. & Suhadolnik, R. J. (1995). Activation of the interferon-inducible enzymes, 2',5'-oligoadenylate synthetase and PKR by human T-cell leukemia virus type I Rex-response element. *Virology* **206**, 913–922.
- Mori, S., Jewett, A., Cavalcanti, M., Murakami-Mori, K., Nakamura, S. & Bonavida, B. (1998). Differential regulation of human NK cell-associated gene expression following activation by IL-2, IFN-alpha and PMA/ionomycin. *International Journal of Oncology* **12**, 1165–1170.
- Mossman, K., Upton, C., Buller, R. M. L. & McFadden, G. (1995). Species specificity of ectromelia virus and vaccinia interferon- $\gamma$  binding proteins. *Virology* **208**, 762–769.
- Mrkic, B., Pavlovic, J., Rulicke, T., Volpe, P., Buchholz, C. J., Hourcade, D., Atkinson, J. P., Aguzzi, A. & Cattaneo, R. (1998). Measles virus spread and pathogenesis in genetically modified mice. *Journal of Virology* **72**, 7420–7427.
- Muller, M., Laxton, C., Briscoe, J., Schindler, C., Improtta, T., Darnell, J. E., Jr, Stark, G. R. & Kerr, I. M. (1993). Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon- $\alpha$  and - $\gamma$  signal transduction pathways. *EMBO Journal* **12**, 4221–4228.
- Muller, U., Steinhoff, U., Reis, L. F., Hemmi, S., Pavlovic, J., Zinkernagel, R. M. & Aguet, M. (1994). Functional role of type I and type II interferons in antiviral defense. *Science* **264**, 1918–1921.
- Murphy, T. L., Cleveland, M. G., Kulesza, P., Magram, J. & Murphy, K. M. (1995). Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. *Molecular and Cellular Biology* **15**, 5258–5267.
- Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., Akira, S. & Kishimoto, T. (1997). Structure and function of a new STAT-induced STAT inhibitor. *Nature* **387**, 924–929.
- Nelson, N., Marks, M. S., Driggers, P. H. & Ozato, K. (1993). Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. *Molecular and Cellular Biology* **13**, 588–599.
- Nguyen, H., Lin, R. & Hiscott, J. (1997). Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins. *Oncogene* **15**, 1425–1435.
- Nilsen, T. W. & Baglioni, C. (1979). Mechanism for discrimination between viral and host mRNA in interferon-treated cells. *Proceedings of the National Academy of Sciences, USA* **76**, 2600–2604.
- Novick, D., Cohen, B. & Rubinstein, M. (1994). The human interferon alpha/beta receptor: characterization and molecular cloning. *Cell* **77**, 391–400.
- Nunez, R. (1999). Revision of the functional analysis and structural features of immortalized dendritic cell lines derived from mice lacking



- both type I and type II interferon receptors. *Immunology Letters* **68**, 173–186.
- O'Connell, M. A., Krause, S., Higuchi, M., Hsuan, J. J., Totty, N. F., Jenny, A. & Keller, W. (1995). Cloning of cDNAs encoding mammalian double-stranded RNA-specific adenosine deaminase. *Molecular and Cellular Biology* **15**, 1389–1397.
- Offermann, M. K., Zimring, J., Mellits, K. H., Hagan, M. K., Shaw, R., Medford, R. M., Mathews, M., Goodbourn, S. & Jagus, R. (1995). Activation of the double-stranded-RNA-activated protein kinase and induction of vascular cell adhesion molecule-1 by poly(I).poly(C) in endothelial cells. *European Journal of Biochemistry* **232**, 28–36.
- Ogasawara, K., Hida, S., Azimi, N., Tagaya, Y., Sato, T., Yokochi-Fukuda, T., Waldmann, T. A., Taniguchi, T. & Taki, S. (1998). Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. *Nature* **391**, 700–703.
- Okamura, H., Kashiwamura, S., Tsutsui, H., Yoshimoto, T. & Nakanishi, K. (1998). Regulation of interferon-gamma production by IL-12 and IL-18. *Current Opinion in Immunology* **10**, 259–264.
- Oura, C. A. L., Powell, P. P. & Parkhouse, R. M. E. (1998). African swine fever: a disease characterized by apoptosis. *Journal of General Virology* **79**, 1427–1438.
- Patterson, J. B., Thomis, D. C., Hans, S. L. & Samuel, C. E. (1995). Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. *Virology* **210**, 508–511.
- Pavlovic, J., Zurcher, T., Haller, O. & Staeheli, P. (1990). Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. *Journal of Virology* **64**, 3370–3375.
- Pavlovic, J., Haller, O. & Staeheli, P. (1992). Human and mouse Mx proteins inhibit different steps of the influenza virus multiplication cycle. *Journal of Virology* **66**, 2564–2569.
- Penix, L. A., Sweetser, M. T., Weaver, W. M., Hoeffler, J. P., Kerppola, T. K. & Wilson, C. B. (1996). The proximal regulatory element of the interferon-gamma promoter mediates selective expression in T cells. *Journal of Biological Chemistry* **271**, 31964–31972.
- Pine, R. (1992). Constitutive expression of an ISGF2/IRF-1 transgene leads to interferon-independent activation of interferon-inducible genes and resistance to virus infection. *Journal of Virology* **66**, 4470–4478.
- Piskurich, J. F., Linhoff, M. W., Wang, Y. & Ting, J. P. (1999). Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. *Molecular and Cellular Biology* **19**, 431–440.
- Pitha, P. M. & Au, W.-C. (1995). Induction of interferon alpha gene expression. *Seminars in Virology* **6**, 151–159.
- Polson, A. G. & Bass, B. L. (1994). Preferential selection of adenosines for modification by double-stranded RNA adenosine deaminase. *EMBO Journal* **13**, 5701–5711.
- Polson, A. G., Bass, B. L. & Casey, J. L. (1996). RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. *Nature* **380**, 454–456.
- Powell, P. P., Dixon, L. K. & Parkhouse, R. M. (1996). An I $\kappa$ B homolog encoded by African swine fever virus provides a novel mechanism for downregulation of proinflammatory cytokine responses in host macrophages. *Journal of Virology* **70**, 8527–8533.
- Qiu, Y. & Krug, R. M. (1994). The influenza virus NS1 protein is a poly(A)-binding protein that inhibits nuclear export of mRNAs containing poly(A). *Journal of Virology* **68**, 2425–2432.
- Qureshi, S. J., Leung, S., Kerr, I. M., Stark, G. R. & Darnell, J. E., Jr (1996). Function of Stat2 protein in transcriptional activation by alpha interferon. *Molecular and Cellular Biology* **16**, 288–293.
- Ramaiah, K., Davies, M. V., Chen, J. J. & Kaufman, R. J. (1994). Expression of mutant eukaryotic initiation factor 2 $\alpha$  subunit (eIF-2 $\alpha$ ) reduces inhibition of guanine nucleotide exchange activity of eIF-2 $\beta$  mediated by eIF-2 $\alpha$  phosphorylation. *Molecular and Cellular Biology* **14**, 4546–4553.
- Ramana, C. V., Grammatikakis, N., Chernov, M., Nguyen, H., Goh, K. C., Williams, B. R. & Stark, G. R. (2000). Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. *EMBO Journal* **19**, 263–272.
- Reis, L. F. L., Harada, H., Wolchok, J. D., Taniguchi, T. & Vilcek, J. (1992). Critical role of a common transcription factor, IRF-1, in the regulation of IFN- $\beta$  and IFN-inducible genes. *EMBO Journal* **11**, 185–193.
- Reiter, Z. (1993). Interferon – major regulator of natural killer cell-mediated cytotoxicity. *Journal of Interferon Research* **13**, 247–257.
- Revilla, Y., Callejo, M., Rodriguez, J. M., Culebras, E., Nogal, M. L., Salas, M. L., Vinuela, E. & Fresno, M. (1998). Inhibition of nuclear factor  $\kappa$ B activation by a virus-encoded I $\kappa$ B-like protein. *Journal of Biological Chemistry* **273**, 5405–5411.
- Rincon, M., Enslin, H., Raingeaud, J., Recht, M., Zapton, T., Su, M. S., Penix, L. A., Davis, R. J. & Flavell, R. A. (1998). Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. *EMBO Journal* **17**, 2817–2829.
- Rivas, C., Gil, J., Melkova, Z., Esteban, M. & Diaz-Guerra, M. (1998). Vaccinia virus E3L protein is an inhibitor of the interferon (IFN)-induced 2–5A synthetase enzyme. *Virology* **243**, 406–414.
- Robertson, H. D. & Mathews, M. B. (1996). The regulation of the protein kinase PKR by RNA. *Biochimie* **78**, 909–914.
- Rojas, R., Roman, J., Torres, A., Ramirez, R., Carracedo, J., Lopez, R., Garcia, J. M., Martin, C. & Pintado, O. (1996). Inhibition of apoptotic cell death in B-CLL by interferon gamma correlates with clinical stage. *Leukemia* **10**, 1782–1788.
- Ronco, L. V., Karpova, A. Y., Vidal, M. & Howley, P. M. (1998). Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. *Genes & Development* **12**, 2061–2072.
- Rosmurduc, O., Sirma, H., Soussan, P., Gordien, E., Lebon, P., Horisberger, M., Bréchet, C. & Kremsdorf, D. (1999). Inhibition of interferon-inducible MxA protein expression by hepatitis B virus capsid protein. *Journal of General Virology* **80**, 1253–1262.
- Rousseau, V., Cremer, I., Laurent, E., Riviere, I., Aguet, M. & De Maeyer, E. (1995). Antiviral activity of autocrine interferon-beta requires the presence of a functional interferon type I receptor. *Journal of Interferon and Cytokine Research* **15**, 785–789.
- Roy, S., Katze, M. G., Parkin, N. T., Ederly, I., Hovanessian, A. G. & Sonenberg, N. (1990). Control of the interferon-induced 68-kilodalton protein kinase by the HIV-1 tat gene product. *Science* **247**, 1216–1219.
- Rysiecki, G., Gewert, D. R. & Williams, B. R. (1989). Constitutive expression of a 2',5'-oligoadenylate synthetase cDNA results in increased antiviral activity and growth suppression. *Journal of Interferon Research* **9**, 649–657.
- Sakatsume, M., Igarashi, K., Winestock, K. D., Garotta, G., Larner, A. C. & Finbloom, D. S. (1995). The Jak kinases differentially associate with the alpha and beta (accessory factor) chains of the interferon gamma receptor to form a functional receptor unit capable of activating STAT transcription factors. *Journal of Biological Chemistry* **270**, 17528–17534.
- Salkowski, C. A., Kopydlowski, K., Blanco, J., Cody, M. J., McNally, R. & Vogel, S. N. (1999). IL-12 is dysregulated in macrophages from IRF-1 and IRF-2 knockout mice. *Journal of Immunology* **163**, 1529–1536.

- Samuel, C. E. (1998).** Reoviruses and the interferon system. *Current Topics in Microbiology and Immunology* **233**, 125–145.
- Sangfelt, O., Erickson, S., Castro, J., Heiden, T., Gustafsson, A., Einhorn, S. & Grander, D. (1999).** Molecular mechanisms underlying interferon- $\alpha$ -induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. *Oncogene* **18**, 2798–2810.
- Sato, M., Tanaka, N., Hata, N., Oda, E. & Taniguchi, T. (1998a).** Involvement of the IRF family transcription factor IRF-3 in virus-induced activation of the IFN-beta gene. *FEBS Letters* **425**, 112–116.
- Sato, M., Hata, N., Asagiri, M., Nakaya, T., Taniguchi, T. & Tanaka, N. (1998b).** Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. *FEBS Letters* **441**, 106–110.
- Scadden, A. D. & Smith, C. W. (1997).** A ribonuclease specific for inosine-containing RNA: a potential role in antiviral defence? *EMBO Journal* **16**, 2140–2149.
- Schafer, S. L., Lin, R., Moore, P. A., Hiscott, J. & Pitha, P. M. (1998).** Regulation of type I interferon gene expression by interferon regulatory factor-3. *Journal of Biological Chemistry* **273**, 2714–2720.
- Schindler, C. (1998).** STATs as activators of apoptosis. *Trends in Cell Biology* **8**, 97–98.
- Schindler, C., Fu, X.-Y., Improta, T., Aebersold, R. & Darnell, J. E., Jr (1992).** Proteins of transcription factor ISGF-3: one gene encodes the 91- and 84-kDa proteins that are activated by interferon  $\alpha$ . *Proceedings of the National Academy of Sciences, USA* **89**, 7836–7839.
- Schneider-Schaulies, S., Schneider-Schaulies, J., Schuster, A., Bayer, M., Pavlovic, J. & ter Meulen, V. (1994).** Cell type-specific MxA-mediated inhibition of measles virus transcription in human brain cells. *Journal of Virology* **68**, 6910–6917.
- Sekimoto, T., Nakajima, K., Tachibana, T., Hirano, T. & Yoneda, Y. (1996).** Interferon-gamma-dependent nuclear import of Stat1 is mediated by the GTPase activity of Ran/TC4. *Journal of Biological Chemistry* **271**, 31017–31020.
- Sharp, T. V., Schwemmler, M., Jeffrey, I., Laing, K., Mellor, H., Proud, C. G., Hilse, K. & Clemens, M. J. (1993).** Comparative analysis of the regulation of the interferon-inducible protein kinase PKR by Epstein-Barr virus RNAs EBER-1 and EBER-2 and adenovirus VAI RNA. *Nucleic Acids Research* **21**, 4483–4490.
- Sharp, T. V., Moonan, F., Romashko, A., Joshi, B., Barber, G. N. & Jagus, R. (1998).** The vaccinia virus E3L gene product interacts with both the regulatory and the substrate binding regions of PKR: implications for PKR autoregulation. *Virology* **250**, 302–315.
- Sharp, T. V., Raine, D. A., Gewert, D. R., Joshi, B., Jagus, R. & Clemens, M. J. (1999).** Activation of the interferon-inducible (2'-5') oligoadenylate synthetase by the Epstein-Barr virus RNA, EBER-1. *Virology* **257**, 303–313.
- Shimizu, K., Iguchi, A., Gomyou, R. & Ono, Y. (1999).** Influenza virus inhibits cleavage of the HSP70 pre-mRNAs at the polyadenylation site. *Virology* **254**, 213–219.
- Shuai, K., Stark, G. R., Kerr, I. M. & Darnell, J. E., Jr (1993).** A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. *Science* **261**, 1744–1746.
- Shuai, K., Horvath, C. M., Huang, L. H., Qureshi, S. A., Cowburn, D. & Darnell, J. E., Jr (1994).** Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. *Cell* **76**, 821–828.
- Silverman, R. H. (1997).** 2-5A-dependent RNase L: a regulated endoribonuclease in the interferon system. In *Ribonucleases: Structure and Function*, pp. 515–551. Edited by G. D'Alessio & J. F. Riordan. New York: Academic Press.
- Silverman, R. H. & Cirino, N. M. (1997).** RNA decay by the interferon-regulated 2-5A system as a host defense against viruses. In *mRNA Metabolism and Post-transcriptional Gene Regulation*, pp. 295–309. Edited by J. B. Hartford & D. R. Morris. New York: Wiley-Liss Inc.
- Singh, S. M., Yanagawa, H., Hanibuchi, M., Miki, T., Okamura, H. & Sone, S. (2000).** Augmentation by interleukin-18 of MHC-nonrestricted killer activity of human peripheral blood mononuclear cells in response to interleukin-12. *International Journal of Immunopharmacology* **22**, 35–43.
- Snapper, C. M. & Paul, W. E. (1987).** Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. *Science* **236**, 944–947.
- Snapper, C. M., Peschel, C. & Paul, W. E. (1988).** IFN-gamma stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. *Journal of Immunology* **140**, 2121–2127.
- Snapper, C. M., McIntyre, T. M., Mandler, R., Pecanha, L. M., Finkelman, F. D., Lees, A. & Mond, J. J. (1992).** Induction of IgG3 secretion by interferon gamma: a model for T cell-independent class switching in response to T cell-independent type 2 antigens. *Journal of Experimental Medicine* **175**, 1367–1371.
- Sprent, J., Zhang, X., Sun, S. & Tough, D. (1999).** T-cell turnover in vivo and the role of cytokines. *Immunology Letters* **65**, 21–25.
- Srivastava, S. P., Kumar, K. U. & Kaufman, R. J. (1998).** Phosphorylation of eukaryotic translation initiation factor 2 mediates apoptosis in response to activation of the double-stranded RNA-dependent protein kinase. *Journal of Biological Chemistry* **273**, 2416–2423.
- Staheli, P., Haller, O., Boll, W., Lindenmann, J. & Weissman, C. (1986).** Mx protein: constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to influenza virus. *Cell* **17**, 147–158.
- Staheli, P., Grob, R., Meier, E., Sutcliffe, J. G. & Haller, O. (1988).** Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation. *Molecular and Cellular Biology* **8**, 4518–4523.
- Staheli, P., Pitossi, F. & Pavlovic, J. (1993).** Mx proteins: GTPases with antiviral activity. *Trends in Cell Biology* **3**, 268–272.
- Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H. & Schreiber, R. D. (1998).** How cells respond to interferons. *Annual Review of Biochemistry* **67**, 227–264.
- Starr, R. & Hilton, D. J. (1999).** Negative regulation of the JAK/STAT pathway. *BioEssays* **21**, 47–52.
- Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A. & Hilton, D. J. (1997).** A family of cytokine-inducible inhibitors of signalling. *Nature* **387**, 917–921.
- Steinhoff, U., Muller, U., Schertler, A., Hengartner, H., Aguet, M. & Zinkernagel, R. M. (1995).** Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice. *Journal of Virology* **69**, 2153–2158.
- Stranden, A. M., Staeheli, P. & Pavlovic, J. (1993).** Function of the mouse Mx1 protein is inhibited by overexpression of the PB2 protein of influenza virus. *Virology* **197**, 642–651.
- Subramaniam, P. S. & Johnson, H. M. (1997).** A role for the cyclin-dependent kinase inhibitor p21 in the G1 cell cycle arrest mediated by the type I interferons. *Journal of Interferon and Cytokine Research* **17**, 11–15.
- Subramaniam, P. S., Cruz, P. E., Hobeika, A. C. & Johnson, H. M. (1998).** Type I interferon induction of the Cdk-inhibitor p21WAF1 is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line. *Oncogene* **16**, 1885–1890.
- Symons, J. A., Alcami, A. & Smith, G. L. (1995).** Vaccinia virus encodes

- a soluble type I interferon receptor of novel structure and broad species specificity. *Cell* **81**, 551–560.
- Szabo, S. J., Jacobson, N. G., Dighe, A. S., Gubler, U. & Murphy, K. M. (1995).** Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. *Immunity* **2**, 665–675.
- Takaoka, A., Tanaka, N., Mitani, Y., Miyazaki, T., Fujii, H., Sato, M., Kovarik, P., Decker, T., Schlessinger, J. & Taniguchi, T. (1999).** Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN- $\gamma$ , but not IFN- $\alpha$ , signaling. *EMBO Journal* **18**, 2480–2488.
- Takizawa, T., Fukuda, R., Miyawaki, T., Ohashi, K. & Nakanishi, Y. (1995).** Activation of the apoptotic Fas antigen-encoding gene upon influenza virus infection involving spontaneously produced beta-interferon. *Virology* **209**, 288–296.
- Takizawa, T., Ohashi, K. & Nakanishi, Y. (1996).** Possible involvement of double-stranded RNA-activated protein kinase in cell death by influenza virus infection. *Journal of Virology* **70**, 8128–8132.
- Tan, S. L. & Katze, M. G. (1998).** Biochemical and genetic evidence for complex formation between the influenza A virus NS1 protein and the interferon-induced PKR protein kinase. *Journal of Interferon and Cytokine Research* **18**, 757–766.
- Tan, S. L. & Katze, M. G. (1999).** The emerging role of the interferon-induced PKR protein kinase as an apoptotic effector: a new face of death? *Journal of Interferon and Cytokine Research* **19**, 543–554.
- Tanaka, N., Sato, M., Lamphier, M. S., Nozawa, H., Oda, E., Noguchi, S., Schreiber, R. D., Tsujimoto, Y. & Taniguchi, T. (1998).** Type I interferons are essential mediators of apoptotic death in virally infected cells. *Genes and Cells* **3**, 29–37.
- Tay, C. H., Yu, L. Y., Kumar, V., Mason, L., Ortaldo, J. R. & Welsh, R. M. (1999).** The role of LY49 NK cell subsets in the regulation of murine cytomegalovirus infections. *Journal of Immunology* **162**, 718–726.
- Taylor, D. R., Shi, S. T., Romano, P. R., Barber, G. N. & Lai, M. M. (1999).** Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. *Science* **285**, 107–110.
- Thanos, D. (1996).** Mechanisms of transcriptional synergism of eukaryotic genes. The interferon-beta paradigm. *Hypertension* **27**, 1025–1029.
- Tominaga, K., Yoshimoto, T., Torigoe, K., Kurimoto, M., Matsui, K., Hada, T., Okamura, H. & Nakanishi, K. (2000).** IL-12 synergizes with IL-18 or IL-1 $\beta$  for IFN- $\gamma$  production from human T cells. *International Immunology* **12**, 151–160.
- Tough, D. F., Borrow, P. & Sprent, J. (1996).** Induction of bystander T cell proliferation by viruses and type I interferon in vivo. *Science* **272**, 1947–1950.
- Tough, D. F., Sun, S., Zhang, X. & Sprent, J. (1999).** Stimulation of naive and memory T cells by cytokines. *Immunology Reviews* **170**, 39–47.
- Trinchieri, G. (1995).** Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. *Annual Review of Immunology* **13**, 251–276.
- Trowsdale, J., Hanson, I., Mockridge, I., Beck, S., Townsend, A. & Kelly, A. (1990).** Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters. *Nature* **348**, 741–744.
- Twu, J. S. & Schloemer, R. H. (1989).** Transcription of the human beta interferon gene is inhibited by hepatitis B virus. *Journal of Virology* **63**, 3065–3071.
- Upton, C., Mossman, K. & McFadden, G. (1992).** Encoding of a homolog of the IFN- $\gamma$  receptor by myxoma virus. *Science* **258**, 1369–1372.
- Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R. & Verma, I. M. (1996).** Suppression of TNF-alpha-induced apoptosis by NF-kappaB. *Science* **274**, 787–789.
- Van Antwerp, D. J., Martin, S. J., Verma, I. M. & Green, D. R. (1998).** Inhibition of TNF-induced apoptosis by NF-kappa B. *Trends in Cell Biology* **8**, 107–111.
- van den Broek, M. F., Muller, U., Huang, S., Aguet, M. & Zinkernagel, R. M. (1995a).** Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. *Journal of Virology* **69**, 4792–4796.
- van den Broek, M. F., Muller, U., Huang, S., Zinkernagel, R. M. & Aguet, M. (1995b).** Immune defence in mice lacking type I and/or type II interferon receptors. *Immunology Reviews* **148**, 5–18.
- Veals, S. A., Schindler, C., Leonard, D., Fu, X. Y., Aebersold, R., Darnell, J. E., Jr & Levy, D. E. (1992).** Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins. *Molecular and Cellular Biology* **12**, 3315–3324.
- Vilcek, J. & Sen, G. (1996).** Interferons and other cytokines. In *Fields Virology*, 3rd edn, pp. 375–399. Edited by B. N. Fields, D. M. Knipe & P. M. Howley. Philadelphia: Lippincott-Raven.
- Visvanathan, K. V. & Goodbourn, S. (1989).** Double-stranded RNA activates binding of NF- $\kappa$ B to an inducible element in the human  $\beta$ -interferon promoter. *EMBO Journal* **8**, 1129–1138.
- Wang, C. Y., Mayo, M. W. & Baldwin, A. S., Jr (1996).** TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. *Science* **274**, 784–787.
- Watanabe, N., Sakakibara, J., Hovanessian, A. G., Taniguchi, T. & Fujita, T. (1991).** Activation of IFN- $\beta$  element by IRF-1 requires a post-translational event in addition to IRF-1 synthesis. *Nucleic Acids Research* **19**, 4421–4428.
- Wathelet, M. G., Lin, C. H., Parekh, B. S., Ronco, L. V., Howley, P. M. & Maniatis, T. (1998).** Virus infection induces the assembly of coordinately activated transcription factors on the IFN- $\beta$  enhancer in vivo. *Molecular Cell* **1**, 507–518.
- Weaver, B. K., Kumar, K. P. & Reich, N. C. (1998).** Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAFI. *Molecular and Cellular Biology* **18**, 1359–1368.
- Weihua, X., Ramanujam, S., Lindner, D. J., Kudravalli, R. D., Freund, R. & Kalvakolanu, D. V. (1998).** The polyoma virus T antigen interferes with interferon-inducible gene expression. *Proceedings of the National Academy of Sciences, USA* **95**, 1085–1090.
- Wen, Z., Zhong, Z. & Darnell, J. E. (1995).** Maximal activation of transcription by STAT1 and STAT3 requires both tyrosine and serine phosphorylation. *Cell* **82**, 241–250.
- Whitten, T. M., Quets, A. T. & Schloemer, R. H. (1991).** Identification of the hepatitis B virus factor that inhibits expression of the beta interferon gene. *Journal of Virology* **65**, 4699–4704.
- Williams, B. R. (1999).** PKR; a sentinel kinase for cellular stress. *Oncogene* **18**, 6112–6120.
- Wong, A. H., Tam, N. W., Yang, Y. L., Cuddihy, A. R., Li, S., Kirchoff, S., Hauser, H., Decker, T. & Koromilas, A. E. (1997).** Physical association between STAT1 and the interferon-inducible protein kinase PKR and implications for interferon and double-stranded RNA signaling pathways. *EMBO Journal* **16**, 1291–1304.
- Wu, M., Lee, H., Bellas, R. E., Schauer, S. L., Arsur, M., Katz, D., FitzGerald, M. J., Rothstein, T. L., Sherr, D. H. & Sonenshein, G. E. (1996).** Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. *EMBO Journal* **15**, 4682–4690.



- Xu, X., Fu, X. Y., Plate, J. & Chong, A. S. (1998). IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. *Cancer Research* **58**, 2832–2837.
- Yan, H., Krishnan, K., Greenlund, A. C., Gupta, S., Lim, J. T. E., Schreiber, R. D., Schindler, C. W. & Krolewski, J. J. (1996). Phosphorylated interferon- $\alpha$  receptor 1 subunit (IFN $\alpha$ R1) acts as a docking site for the latent form of the 113 kDa STAT2 protein. *EMBO Journal* **15**, 1064–1074.
- Yang, Y.-L., Reis, L. F. L., Pavlovic, J., Aguzzi, A., Schafer, R., Kumar, A., Williams, B. R. G., Aguet, M. & Weissmann, C. (1995). Deficient signalling in mice devoid of double-stranded RNA-dependent protein kinase, PKR. *EMBO Journal* **14**, 6095–6106.
- Yang, D. D., Conze, D., Whitmarsh, A. J., Barrett, T., Davis, R. J., Rincon, M. & Flavell, R. A. (1998). Differentiation of CD4<sup>+</sup> T cells to Th1 cells requires MAP kinase JNK2. *Immunity* **9**, 575–585.
- Yeow, W. S., Lawson, C. M. & Beilharz, M. W. (1998). Antiviral activities of individual murine IFN- $\alpha$  subtypes in vivo: intramuscular injection of IFN expression constructs reduces cytomegalovirus replication. *Journal of Immunology* **160**, 2932–2939.
- Yeow, W. S., Au, W. C., Juang, Y. T., Fields, C. D., Dent, C. L., Gewert, D. R. & Pitha, P. M. (2000). Reconstitution of virus-mediated expression of interferon- $\alpha$  genes in human fibroblast cells by ectopic interferon regulatory factor-7. *Journal of Biological Chemistry* **275**, 6313–6320.
- Yeung, M. C., Liu, J. & Lau, A. S. (1996). An essential role for the interferon-inducible, double-stranded RNA-activated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells. *Proceedings of the National Academy of Sciences, USA* **93**, 12451–12455.
- Yokoo, J., Gotoh, B., Komatsu, T., Takeuchi, K. & Miyadai, T. (1999). Replication-incompetent Sendai virus can suppress the antiviral action of type I interferon. *Archives of Virology* **144**, 1043–1055.
- Yokosawa, N., Kubota, T. & Fujii, N. (1998). Poor induction of interferon-induced 2',5'-oligoadenylate synthetase (2–5 AS) in cells persistently infected with mumps virus is caused by decrease of STAT-1 $\alpha$ . *Archives of Virology* **143**, 1985–1992.
- Yoneyama, M., Suhara, W., Fukuhara, Y., Sato, M., Ozato, K. & Fujita, T. (1996). Autocrine amplification of type I interferon gene expression mediated by interferon stimulated gene factor 3 (ISGF3). *Journal of Biochemistry* **120**, 160–169.
- Yoneyama, M., Suhara, W., Fukuhara, Y., Fukuda, M., Nishida, E. & Fujita, T. (1998). Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. *EMBO Journal* **17**, 1087–1095.
- York, I. A. & Rock, K. L. (1996). Antigen processing and presentation by the class I major histocompatibility complex. *Annual Review of Immunology* **14**, 369–396.
- Yoshimoto, T., Takeda, K., Tanaka, T., Ohkusu, K., Kashiwamura, S., Okamura, H., Akira, S. & Nakanishi, K. (1998). IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. *Journal of Immunology* **161**, 3400–3407.
- Young, H. A. (1996). Regulation of interferon-gamma gene expression. *Journal of Interferon and Cytokine Research* **16**, 563–568.
- Young, D. F., Didcock, L., Goodbourn, S. & Randall, R. E. (2000). Paramyxoviridae use distinct virus-specific mechanisms to circumvent the interferon response. *Virology* **269**, 383–390.
- Yue, Z. & Shatkin, A. J. (1997). Double-stranded RNA-dependent protein kinase (PKR) is regulated by reovirus structural proteins. *Virology* **234**, 364–371.
- Zamanian-Daryoush, M., Mogensen, T. H., DiDonato, J. A. & Williams, B. R. (2000). NF- $\kappa$ B activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF- $\kappa$ B-inducing kinase and I $\kappa$ B kinase. *Molecular and Cellular Biology* **20**, 1278–1290.
- Zhang, L. & Pagano, J. S. (2000). Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1. *Journal of Virology* **74**, 1061–1068.
- Zhang, J. J., Vinkemeier, U., Gu, W., Chakravarti, D., Horvath, C. M. & Darnell, J. E., Jr (1996). Two contact regions between Stat1 and CBP/p300 in interferon- $\gamma$  signaling. *Proceedings of the National Academy of Sciences, USA* **93**, 15092–15096.
- Zhang, F., Wang, D. Z., Boothby, M., Penix, L., Flavell, R. A. & Aune, T. M. (1998a). Regulation of the activity of IFN-gamma promoter elements during Th cell differentiation. *Journal of Immunology* **161**, 6105–6112.
- Zhang, J. J., Zhao, Y., Chait, B. T., Lathem, W. W., Ritz, M., Knippers, R. & Darnell, J. E., Jr (1998b). Ser727-dependent recruitment of MCM5 by Stat1 $\alpha$  in IFN- $\gamma$ -induced transcriptional activation. *EMBO Journal* **17**, 6963–6971.
- Zhang, X., Sun, S., Hwang, I., Tough, D. F. & Sprent, J. (1998c). Potent and selective stimulation of memory-phenotype CD8<sup>+</sup> T cells in vivo by IL-15. *Immunity* **8**, 591–599.
- Zhao, H., De, B. P., Das, T. & Banerjee, A. K. (1996). Inhibition of human parainfluenza virus-3 replication by interferon and human MxA. *Virology* **220**, 330–338.
- Zhou, A., Paranjape, J., Brown, T. L., Nie, H., Naik, S., Dong, B., Chang, A., Trapp, B., Fairchild, R., Colmenares, C. & Silverman, R. H. (1997). Interferon action and apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L. *EMBO Journal* **16**, 6355–6363.
- Zhou, A., Paranjape, J. M., Der, S. D., Williams, B. R. & Silverman, R. H. (1999). Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. *Virology* **258**, 435–440.
- Zhu, M., John, S., Berg, M. & Leonard, W. J. (1999). Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFN $\gamma$ -mediated signaling. *Cell* **96**, 121–130.
- Zimring, J. C., Goodbourn, S. & Offermann, M. K. (1998). Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription. *Journal of Virology* **72**, 701–707.